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ABSTRACT
Whooping cough is a common childhood disease caused by infection with the bacterium
Bordetella pertussis or Bordetella parapertussis. Although there are both whole-cell and
acellular vaccines commercially available, whooping cough has been called the worst-controlled
vaccine-preventable disease in existence today. Recent data indicates that there were
approximately 16 million cases of whooping cough worldwide in 2008, resulting in 195,000
deaths. The majority of these deaths were in developing countries, in infants that were too young
to have been vaccinated, or who had not received their full course of vaccinations. Although
previously considered under control within most developed countries due to widespread
vaccination, a resurgence of whooping cough has been occurring in many developed countries
including Canada, the United States, and the United Kingdom. Recent outbreaks in North
America have underscored the need for new and more effective vaccines that can be given
during the neonatal period, to protect infants in the crucial first few months of life, when they are
most susceptible to the disease, and that will provide long-lasting protection against pertussis.
The neonatal immune system has several functional differences from the adult system,
and there are specific difficulties that must be overcome when attempting to create a vaccine that
can be effective in the neonate. The inherent Th2 bias of the infant immune system is a key
difference, with the induction of Th1 type humoral and cell-mediated immune responses being
more difficult to achieve due to this state, although not impossible. Another important issue is
the presence of maternal antibodies in infants, which can also interfere with vaccination and
achieving a sufficient primary immune response.
We tested several adjuvants for immunogenicity, including various dosages and forms of
cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODN), innate defense regulator
peptides (IDRP), and polyphosphazenes (PP), in order to design a novel adjuvant platform that
could be combined with our pertussis vaccine antigen, pertussis toxoid (PTd). After selection of
the appropriate form and dose of each adjuvant component, we tested the ability of various
formulations of the adjuvants in adult and neonatal mice to induce mixed Th1 and Th2 humoral
responses, in order to further refine our adjuvant platform. We found that a ratio of 1:2:1 of CpG
ODN: IDRP: PP was ideal, and demonstrated that the pre-complexing of the IDRP and CpG
ODN components was able to induce significantly higher Th1 (IgG2a) antibody titres than when
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the vaccines were not complexed. Our vaccine platform was able to induce strong Th1 and Th2
antibody titres in both adult and neonatal BALB/c mice, with the immune response being of a
mixed Th1/Th2 type. However, there was an especially significant increase in the Th1 type
humoral response using our novel adjuvant platform when compared to immunization with either
current commercial vaccines such as Quadracel®, or when using the standard vaccine adjuvant
alum. The Th1 antibody response was extremely long-lasting, with strong IgG2a titres being
found up to 2 years post-vaccination.
When an examination of the cell-mediated immune response was performed in adult and
neonatal BALB/c mice, it was found that a strong secretory IFN- (Th1) response was present
post-vaccination in the splenocytes of mice immunized with our novel vaccine. This
corresponded with a large number of IFN- secreting cells present as visualized through
ELISPOTs. The IL-5 (Th2) response, however, was found to be decreased in mice that received
our novel vaccine as compared to mice vaccinated with Quadracel®, with no detectable cytokine
secreted by stimulated splenocytes in vitro, and few to no IL-5 secreting cells visible through
ELISPOT.
In order to further improve our vaccine, a second antigen, pertactin (PRN), was added to
the formulation, and neonatal mice were immunized and subsequently challenged with live B.
pertussis. The mice that received the two-antigen vaccine were completely protected against the
bacterial infection, and showed strong humoral Th1 and Th2 responses. Several animals that
received our two-antigen vaccine showed complete bacterial clearance. This full protection and
clearance was superior to the results seen using the commercial vaccine Quadracel®.
Finally, the adjuvant platform was further examined to test its variability and cell
recruitment functions. The novel adjuvant platform was able to induce a strong mixed Th1 and
Th2 humoral response when combined with a different vaccine antigen, hepatitis B surface
antigen (HBsAg), and showed similar results to those seen using PTd, with a significant increase
in the Th1 (IgG2a) antibody response when compared to immunization of mice with alum as an
adjuvant. Replacing the CpG ODN component of the adjuvant platform with Poly I:C induced
lower Th1 antibody responses when the vaccine was delivered subcutaneously or intranasally,
however when given intramuscularly it was able to induce IgG2a titres equal to that of the
adjuvant platform containing CpG ODN.
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When the ability of adjuvant platform to recruit cells to the site of injection was
examined, it was determined through histological analysis that the reaction seen was localized
and not systemic, and required the presence of both the adjuvant platform and the vaccine
antigen together at the same site for induction of the inflammatory response. The response seen
at the site of injection was characterized by an influx of neutrophils to the site, with increased
vasculitis and little to no necrosis. There was little to no inflammatory response seen over a 48
hour period in mice injected with the adjuvant platform alone, with the PTd antigen alone, or
with the adjuvant platform and PTd given in different legs, indicating that a site-specific
response is occurring that requires both the presence of the adjuvants and the antigen to be
induced.
In summary, we have developed a novel vaccine formulation against B. pertussis, which
is able to induce strong humoral and cell-mediated immune responses, especially Th1 responses,
in both adult and neonatal mice, with the immune responses induced being long-lasting and
protective against infection. We have also demonstrated that our novel adjuvant platform itself is
adaptable for use with other vaccine antigens and routes of administration, and it may be possible
to adjust its components while maintaining efficacy.
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1CHAPTER 1: LITERATURE REVIEW
1.1 Bordetella pertussis
1.1.1 Overview
The disease whooping cough, resulting from infection with the bacteria Bordetella pertussis
and B.parapertussis is endemic worldwide. While remaining an important cause of infant and
child illness in developing nations, it is also undergoing a resurgence within the developed
world. The disease is most dangerous to infants and young children, in particular those who have
not received their full course of vaccinations. As current pertussis vaccines are not administered
prior to two months of age, there is a significant window of vulnerability present at infancy, the
very time when the human immune system is least capable of dealing with the type of infection
causing the disease. Thus, it is no surprise that the majority of the mortality from pertussis is
seen in very young infants. There is evidence that infants who recover from the disease suffer
from reduced weight gain during early childhood as compared to those that were not infected,
and may also have an increased risk of asthma symptoms and respiratory infections later in life
[1]. Thus, a vaccine is needed that can address the need to immunize earlier in life, and can meet
the specific requirements of stimulating the infant immune system.
1.1.2 B. pertussis
The Bordetella genus encompasses six species including B. pertussis, B. parapertussis, B.
bronchiseptica, B. avium, B. hinzii, and B. holmezii [2].The two species associated with
whooping cough, B. pertussis and B. parapertussis, are closely related with similar morphology
and cause similar disease in humans [3, 4]. Bordetella bronchiseptica is usually found as a
common commensal animal pathogen, however it has been found in humans causing zoonotic
disease, and it has been suggested that this is the species from which both B. parapertussis and
B. pertussis evolved [4, 5]. B. pertussis is a Gram-negative aerobic coccobacillus which attaches
itself to the ciliated epithelial cells of the mucosa in the mammalian upper respiratory tract [3]. It
most commonly acts as an extracellular pathogen, however it is also capable of invading human
alveolar macrophages, and thus functioning in an  intracellular manner [6].The bacterium is
approximately 0.8 μm by 0.4 μm in size, non-encapsulated, non-motile, and non-spore
2producing [3]. B. pertussis is slow-growing, taking at least three to five days to produce pinpoint
colonies, and is most commonly grown on blood-containing medium, as it is nutritionally
fastidious and has a requirement for nicotinamide [5]. It expresses several virulence factors, the
most important being pertussis toxin (PT), a 105kDa protein unique to B. pertussis, which is an
A-B toxin similar to cholera toxin [2, 7]. There are two main subunits, with the A (S1) subunit
being enzymatically active, and the B (S2-S5) oligomer having no enzymatic activity and only
responsible for the binding of the toxin to the cell [7]. The S1 subunit is released into the cell,
and functions as an ADP-ribosyltransferase which ribosylates the Gi subclass of G proteins,
resulting in a disruption of intracellular signalling [7, 8]. Mac-1 (macrophage-1 antigen, also
known as CR3 or CD11b/CD18) has been implicated as the cell surface receptor being bound by
the B oligomer of PT [9]. Adenylat cyclase toxin (ACT) is a hemolysin that is secreted
extracytoplasmically in large quantities by the bacteria. It enters target cells through contact and
after activation by calmodulin within the host cell, functions by enzymatically inhibiting the
natural phagocytic and cytotoxic functions of cells responsible for immune defense including
neutrophils, monocytes, and natural killer (NK) cells [3, 7]. It has also been shown to modulate
host dendritic cell (DC) function through blocking IL-12p70 production, resulting in Th17 cell
promotion and Th1 limitation [10]. Lipopolysaccharide (LPS), also known as endotoxin, a
characteristic component of Gram-negative bacterial cell walls, is also produced by Bordetella
species, and is the pathogen associated molecular pattern (PAMP) that functions as the agonist of
the innate immune pattern recognition reception (PRR) toll-like receptor 4(TLR4). In B.
pertussis, the lipopolysaccharide (LPS) is missing a long O-antigenic chain, thus it is referred to
as lipooligosaccharide (LOS) [7]. LPS and LOS are made up of a saccharide chain and a lipid A
portion, which results in toxic effects. There are also other toxins produced by the bacterium,
including heat-labile toxin (HLT) and tracheal cytotoxin (TCT), the first of which is protoplasm
localized causing tissue damage through dermonecrosis and vasoconstriction, and the second
which is a fragment of the cell wall peptidoglycan and destroys the ciliated cells within the
trachea [2, 3]. Filamentous haemaggultinin (FHA) is a large 220 kDa surface protein of the cell
envelope that is partially responsible for mediating adhesion to the ciliated host cells in the
respiratory tract [2, 7]. Pertactin (PRN) is an autotransporter protein of 68-70 kDa that is also
involved in the binding of the bacterium to the cell [2, 3]. Further involved in mediating host cell
3adhesion are the fimbriae (FIM)-2 and 3 proteins, serotype-specific agglutinins which are found
on the surface of the bacterium [7].
1.1.3 Disease and Clinical Symptoms
Whooping cough is acute respiratory infection, with a characteristic paroxysmal cough,
which causes a “whoop” sound upon inhaling that gives the disease its name. It is transmitted
person to person through airborne droplets, and symptoms begin to appear after an incubation
period of 7-10 days [11]. The catarrhal phase of the disease, where patients are most infective,
lasts from one to two weeks, and is characterized by coughing, fever and rhinorrhea [3, 11]. The
next phase, lasting two to four weeks, is called the paroxysmal phase. This is where the
characteristic “whoop” sounding cough usually appears, most severely at night, with other
attending complications such as vomiting being common [11]. Finally, there is the convalescent
phase of one to three weeks, during which the cough gradually declines. Patients remain
infectious to others for a period of approximately five weeks [3]. Complications arising from
whooping cough are most likely to be seen in young infants, and can include bronchopneumonia
and acute encephalopathy, which is particularly dangerous, with often lethal results [3, 11].
Treatment of the disease involves administration of macrolide antibiotics, most commonly
erythromycin. If given in the early catarrhal phase, antibiotic therapy may be able to reduce or
prevent clinical symptoms, however when administered later in the course of disease, antibiotics
can only reduce transmissibility, and have little effect on symptomology [3, 11].
1.1.4 Epidemiology
There were an estimated 18.4 million cases of whooping cough worldwide in 2004, resulting
in 254,000 deaths [12]. Of these cases, 12.7 million are found in Africa or South-East Asia [12].
The disease causes high morbidity in unvaccinated children, and may still be underestimated or
misdiagnosed in both developed and developing nations [13]. There is a much higher case-
fatality rate in developing nations (approximately 1-3%) as compared to developed countries
(0.04%), which makes the unbalanced distribution of disease cases even more devastating [14].
4Recently in developed nations such as Canada and the United States, there has been an increase
in the number of people infected with pertussis, despite relatively high rates of vaccination
coverage [14-17]. Particularly noticeable is the increase in infections seen among adolescents
and young adults, who can then proceed to infect those too young to be immunized [15]. A major
source of primary exposure for infants has been found to be contact with an infected household
or family member, often an adolescent child who was partially or even fully immunized [15, 16].
Current measures being proposed to deal with the issue include booster vaccination specifically
of immediate family members of young infants (the “cocoon strategy”), a pre-school booster, as
well as vaccination of adolescents in general [15, 18, 19]. Some suggested causes of this disease
resurgence are age-cohort effects, a lack of vaccine coverage, and possible issues with vaccine
effectiveness or waning post-vaccination immunity [17, 20, 21].
1.1.5 Immune Response to Infection
Infection with B. pertussis in infants as young as 4 months old results in induction of T cells
specific for several of the bacterial antigens, such as PT, FHA or PRN, which show the
characteristics of Th1 cells, and are able to secrete the Th-1 type cytokine interferon-(IFN-
and interleukin-2 (IL-2), but not the Th2 cytokines IL-4 or IL-5, in response to antigen
restimulation [22, 23]. It appears that natural infection in humans tends to polarize responding T
cells in the Th1 direction, an initial indication of the importance of the Th1 or cell-mediated
immune response in combating pertussis infection. This was confirmed by studies in mice
showing that T cell-deficient mice were unable to clear pertussis infection, and adoptive transfer
of CD4+ T cells from immune animals was able to mediate protection against bacterial
challenge, even when there was a lack of detectable serum antibody [22, 24]. The subset of T
cells conferring the protective effects were shown to be Th1-like cells that secreted IFN- and
not IL-4 [24]. Although the importance of IFNproduced by Th1 cells has thus been established
in cell-mediated immunity to pertussis, other cells have also been implicated in protection.
Stimulation of NK cells by DC through production of IL-12 and IL-23 results in IFN- early on
in pertussis infection, with a lack of NK cells resulting in an enhanced Th2 response [25]. It has
also recently been shown that the ACT is able to modulate the actions of human DC through
reducing the production of the Th1 promoting cytokine IL-12p70, which results in promotion of
5a Th17 type immune response and an inhibition of the Th1 immune response to infection [10].
IL-12 is also produced by macrophages in response to B. pertussis infection in mice [26].The
Th1 cells induced by infection are detectable in the spleen and lymph nodes of mice within two
to three weeks after infection [23]. When naive mice are infected with pertussis, an acute influx
of immune cells including macrophages, neutrophils and lymphocytes into the lung occurs. This
cell infiltration also occurs in immune mice, however it is less dramatic and more transient by
comparison [23]. There is also a strong induction of IgG antibodies against PT, FHA, PRN, FIM,
ACT, LPS, and other B. pertussis antigens seen after natural infection, and evidence that humoral
immunity does play a role in protection, with both humoral and cell-mediated immune responses
being required for optimal protection [23]. This was shown through the targeted disruption of
immunoglobulin (Ig) heavy-chain genes, with Ig knockout mice developing chronic infection
after B. pertussis infection [27].The antibodies produced were thought to function by inhibition
of bacterial adhesion and uptake, toxin neutralization or opsonizing the bacterium in order to
facilitate phagocytosis [23].
Recent evidence indicates that natural immunity after recovery from infection with pertussis is
substantial, and longer-lasting (possibly up to 30 years) than whole-cell pertussis (Pw) vaccine
induced immunity (6-12 years), which it was originally thought to be similar in duration to [11,
20]. However, the duration of immunity is inherently variable from person to person.
1.1.6 Immune Response to Vaccination
Although there are both whole-cell (Pw) and acellular pertussis (Pa) vaccines available which
have served to decrease the incidence of disease, the clinical correlates of immunity to pertussis
remain unknown. In developing countries, Pw vaccines remain the most commonly used, due to
their lower cost, while many developed nations now exclusively use Pa vaccine [11]. Pw
vaccines are usually inactivated by formalin, and contain whole cell bacteria including PT, ACT,
FHA, and LPS, while Pa vaccines have the LPS and various other cell components removed and
the PT treated to remove its toxicity [7]. Both types of vaccine include an aluminum salt as an
adjuvant, and have been shown to induce strong antibody titres against the included antigens, in
proportion to the number of doses received, and both can result in immunity against infection,
with Pw being suggested to have higher efficacy, but Pa resulting in lower reactogenicity and
6reduced frequency of  systemic and local reactions [7]. There are no clear correlations between
serum antibody levels and protection [28]. Immunization with Pw is similar to natural infection
in its ability to stimulate macrophage production of IL-12 and induce antigen-specific Th1 cells
in mice, resulting in protection against bacterial challenge [26]. In contrast, immunization of
mice with Pa resulted in no detectable production of IL-12 by restimulated macrophages with the
main antigenic components of the vaccine. The addition of IL-12 to Pa is able to enhance its
efficacy through polarization of the T cell response in the Th1 direction, suggesting that the
induction of IL-12 by Pw may be involved in its higher efficacy [26]. There is also a
demonstrated role of IFN- in immunity resulting from Pw vaccination, similar to that seen after
natural infection [27]. This once again contrasts with Pa, which mostly mediates protection
through strong induction of antibody against the included antigens [27]. TLR4 has also been
shown to be important in the DC response to immunization with Pw, with DC activation through
TLR4 resulting in production of IL-23, IL-12, IL-1 and tumor necrosis factor (TNF)-
[29].Thus it appears that Pw tend to induce Th1 type and cellular responses while Pa induce
humoral and Th2 biased responses.
1.2 Overview of the Neonatal Immune System
1.2.1. Characteristics of the Neonatal Immune System
The neonatal immune system, defined as the first 28 days of life in humans, is no longer seen
as immature in nature, but as shifted in its tendencies. During pregnancy, an increase in
hormones such as progesterone assists in the down-regulation of Th1 and pro-inflammatory
responses in the mother, resulting in a Th2 bias [30, 31]. This helps prevent an alloimmune
response to the fetus [32]. This Th2 bias is reflected in the immune system of both the fetus, and
the neonate, and results in a limited capacity to clear intracellular infections. There are also high
levels of functional T-regulatory (Treg) cells (CD4+/CD25high) found in both fetal lymphoid tissue
and neonatal cord blood, which function to suppress the Th1 response in order to prevent
autoimmune reactions to self-antigens [33]. There are high levels of the anti-inflammatory
cytokine IL-10 produced in the neonate, which results in the impairment of neutrophil responses
7[32]. In prematurely born neonates, the IL-10 response to TLR stimulation remains, however
there is a profound deficiency in the IL-12 and IL-23 subunit p40, resulting in an even weaker
Th1 response and greater susceptibility to infection [34]. Recent data has indicated that human
neonatal myeloid dendritic cell (mDC) levels are notably low at birth, and increase to adult levels
within the first year of life, however the levels of plasmacytoid dendritic cells (pDC) in neonates
remains lower than adults until approximately 2 years of age [35].
Newborn infants passively receive antibodies from their mothers. IgG antibodies against
several B. pertussis antigens have been detected in cord blood and serum of infants prior to their
first dose of vaccine, which were likely transferred through transplacental passage of antibody
from the mother [7]. In contrast, no cord blood samples have been found to contain IgM
antibody, and only 5% of infants tested had IgA antibody against pertussis in their serum
samples [7].
Antibodies induced in response to bacterial or viral antigens tend to be short-lived and weak
in the neonate, and remain so until about one year of age [36]. A possible reason for the short-
lived antibody responses in the neonate is the impaired homing ability of long-lived plasmacytes
to the bone marrow [36]. This often results in a complete lack of antibody response or a very
weak response to a vaccine given at birth. However, antigen-specific memory B cells can be
induced in early infancy [37]. Infants are also less able to produce IgG2a antibodies in particular.
The infant antibody response is characterized by a predominance of IgM, although the isotype
switch to IgG is possible, it is dominated by IgG1 and IgG3 antibodies [36]. Neonates are also
very limited in their response to T-independent, such as bacterial capsular polysaccharides and
other carbohydrates, as well as T-dependent antigens [38]. The follicular dendritic cells (FDC) of
neonatal mice are unresponsive, which results in a limited number of germinal centre (GC)
induced in response to antigen stimulation [39]. The immature FDC and resulting delay in GC
induction causes limitations in antibody secreting cell (ASC) differentiation, resulting in limited
primary IgG responses, even when strong immunostimulants such as cytosine-phosphate-
guanosine oligodeoxynucleotides (CpG ODN) are used. In humans, the appearance of fully
mature FDC is thought to occur around two months of age, with GC occurring at approximately
four months [39]. Stromal cells of the bone marrow (including endothelial cells), provide
migration signals, such as vascular cell adhesion molecule (VCAM)-1 and E-selectin, able to
8induce leukocytes to travel into and out of the bone marrow compartment [40]. Plasmablasts
generated in the spleen of neonates successfully migrate to the bone marrow however, due to the
inability of neonatal bone marrow stromal cells to support their survival (due to insufficient bone
marrow stromal cell (BMSC) expression of a proliferation  inducing ligand (APRIL)), the
plasmablasts are unable to survive as ASC [41, 42]. This could explain the lack of antibody
response to very immunogenic antigens in neonates as compared to adults.
Maternal antibodies (MAb) passively transferred to and present in the neonate can interfere
with the humoral response to vaccination in various titre-dependent ways. They can bind to B
cell epitopes of the vaccine antigen, blocking the infant B cells from recognizing their specific
epitopes, or they can bind to and neutralize live vaccines [36]. The presence of MAb tends to not
affect T cell responses, as antigen:MAb immune complexes can be taken up by antigen
presenting cells (APC) and presented to CD4+ and CD8+ T cells successfully through the
fragment crystallizable region- receptor (FcR) [43]. Strategies to avoid MAb interference with
vaccination include increasing the antigen dose, using mucosal routes of immunization (since the
MAb concentration at the mucosa is much lower than in the serum), microencapsulation of
antigen, and developing novel vaccine formulations able to result in prolonged immune
stimulation, so that the MAb levels have time to wane [36, 43].
The decreased CD4+ and CD8+ T cell function in the neonate is due to a suboptimal ability of
APC to interact with the T cells, as well as a low number of APC overall [36, 44]. The mDC of
human neonates express lower levels of major histocompatibility complex II (MHC II) and
cluster of differentiation (CD)80/86, and are impaired in their IL-12p70 and IFN- (resulting in
less IFN- induction) production, resulting in a decreased capacity to mount Th1 type responses
as compared to adult mDC [44, 45]. Human neonatal pDC also have a reduced ability to respond
to stimulation with TLR-7 and TLR-9 agonists with IFN-and IFN- production, even though
they express similar levels of the PRR as adult pDC [37]. This reduced response disappears by
one year of age [35]. However, neonatal mDC and pDC are able to produce equal or greater
amounts of the cytokines IL-1, IL-6, IL-23 and IL-10 in response to TLR ligands as adult cells,
further demonstrating the neonatal bias in the Th-17 and Th-2 direction [45]. It has been
suggested that these results are due to neonatal deficiencies in interferon regulatory factor 3
(IRF-3) activation in mDC, and impaired IRF-7 translocation in human pDC [44].
9Soon after birth, the neonatal gut begins to be colonized by commensal bacteria. Since a
strong inflammatory response to the LPS of Gram-negative bacteria could be dangerous, the
intestinal cells of the neonate temporarily lose their responsiveness to TLR-4 [32]. The initial
post-birth exposure of intestinal epithelial cells to LPS stimulates the upregulation of the
microRNA miR-146a, which represses the TLR-signaling molecule IL-1 receptor-associated
kinase 1 (IRAK1) [46]. This down-regulates the production of the IRAK1 protein in the cells,
and protects the mucosa from damage.
In mice, the neonatal period is less clearly defined than in humans. Although many previous
studies defined one to three day old mice as neonates, the immune maturation of mice at this age
poorly correlates to that of humans. The newborn mouse is less developed than the human, with
a lack of terminal deoxynucleotidyl transferase expression, which is found even in the human
fetus [36]. This relative immaturity can be demonstrated by neonatal thymectomy, which does
not significantly affect future human responses, but drastically affects those seen in mice [36].
However, at the age of one week, mice immunized with weak vaccine antigens (such as
diphtheria toxoid) that do not show primary antibody responses, are able to show clear antibody
responses and induction of memory B cells after subsequent immunizations, indicating that
seven day old mice are a better correlate to the human neonate [36].
1.2.2. Comparison with the Adult Immune System
Although the neonatal immune system is able to successfully produce Th1 type immune
responses, these responses tend to be lower in comparison to those seen in similarly treated
adults. Neonates also have reduced levels of complement components such as complement
component 3d (C3d) in their blood as compared to adults, which may be partially responsible for
their susceptibility to encapsulated bacteria [32, 36]. Vaccines which are able to induce a strong
IgG2a response in adults are often unable to do so in infants [36]. A major difference between
the neonatal and adult immune systems is seen within the DC. Although the cord blood of
neonates indicates that they express similar amounts of TLRs on their monocytes, the response
of neonatal cells to TLR stimulation is different, with less capacity for IL-12p70, IFN- and
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IFN- production, similar or greater for IL-6, IL-23 and IL-1, and far greater ability with
respect to IL-10 production [33]. When LPS is used to stimulate human neonatal DC through
TLR4 activation, there is IL-23 production, however, adult DC produce IL-12, with the resulting
CD4 T cell differentiation favouring Th17 cells in the neonate and Th1 cells in the adult [37].
However, it is possible to induce adult-like T cell responses in the neonate using specific
adjuvants or vaccines, for example the Bacille Calmette-Guérin vaccine [37]. Another important
difference between neonates and adults is the pDC to mDC ratio, which is approximately 3:1 as
compared to 1:3, respectively [44]. This means that there are relatively more DC that can
promote an inflammatory response through IFN- production in the neonate, and less that are
able to induce T cell differentiation in the Th1 direction through IL-12. Although the ability of
neonatal mDC to produce IL-12p70 (contributing to the Th1 response) starts increasing from
birth, the capacity of the mDC to produce the cytokine in response to TLR stimulation remains
less than half of that seen in adult cells, even at 2 years of age [35]. IFN- production by infant
mononuclear cells in response to stimulation with TLR-7 or TLR-8 also remains below adult
levels up to 2 years of age, while the increased neonatal Th17 response, as indicated by higher
than adult levels of IL-23 production at birth, decreases to adult levels within the first year of life
[35]. Finally, there is an increased IL-10 response seen in cord blood from neonates at birth, with
the production of this cytokine decreasing during infancy and dropping to adult levels between
one to two years of age [35].
1.3 Linking the Innate and Adaptive Immune Systems
The innate immune system is phylogenetically conserved, and encoded in fixed germline
receptors such as the TLR [47, 48]. It functions by recognizing damage associated molecular
patterns (DAMP) and PAMP and mounting subsequent immediate non-specific pro-
inflammatory (such as IL-1, IL-6 and IL-8) immune responses [49]. The key difference
between the innate and adaptive immune responses is the specificity and delayed reaction of the
adaptive immune response, which uses gene rearrangement, somatic hypermutation, and Ig-class
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switching, to generate antigen-specific effector cells that can recognize particular epitopes on a
pathogen and results in immune memory [49]. Since the adaptive immune response is improved
through exposure to particular pathogens (with subsequent exposures to a pathogen resulting in a
faster and stronger specific immune response), while the innate immune response does not
depend on prior exposure, the innate immune response is particularly key in the initial few
months of life, when the adaptive response is still being formed. It should be noted that defects in
innate immunity although more rare, are more likely to be lethal than those in adaptive
immunity, however dysfunctional adaptive immunity is responsible for many common problems
such as allergy, tissue graft rejection, and most autoimmune disorders [49]. Successful activation
of both the innate and adaptive immune responses, often through induction of appropriate
cytokines, is key to designing an effective vaccine. There are many linkages between the innate
and adaptive immune system, a key one being in the effector cells used to trigger the immune
responses. Innate responses are immediate and mostly triggered through the detection of
pathogens using PRR on macrophages (M, DC, neutrophils, eosinophils, NK cells, and mast
cells [49]. Some of these same immune cells when activated, subsequently act as APC and
initiate the response of the antigen-specific effector B and CD4+ or CD8+ T cells of the adaptive
immune system. This response requires clonal expansion and differentiation of the effector
lymphocytes, usually requiring three to five days to occur [49]. This combined effect is referred
to as the instruction of the adaptive immune system by the innate immune system. One aspect of
this instruction is the upregulation, through activation of the NF-B (Nuclear factor -light-
chain-enhancer of activated B cells) pathway, of the co-stimulatory molecules CD80 and CD86
on APC such as the DC [47]. PRR and other molecules, such as C-reactive protein, function
through opsonization, activation of complement and pro-inflammatory pathways, as well as
through induction of apoptosis [49]. PRR can be expressed extracellularly as in TLR-4, or
intracellularly as in nucleotide-binding oligomerization domain (NOD) proteins (as well as TLR-
9), both of which respond to LPS. When bound by their respective ligand, TLR induce
expression of various host defense mechanisms, such as the production of pro-inflammatory
cytokines, upregulation of co-stimulatory molecules, and production of antimicrobial peptides
[49].TLR can function through pathways that are dependent or independent of the adaptor
protein myeloid differentiation primary response gene 88 (MyD88), with most TLR using the
MyD88-dependent pathway, resulting in the release of NF-B, a conserved transcription factor
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involved in DC development and Ig light chain transcription, which promotes the induction of
pro-inflammatory responses [47, 49]. The MyD88-independent pathway, used in TLR3 and
TLR4 responses, activates the transcription factor IRF-3, which can induce IFNproduction
[47].
One of the key molecules involved in the linking of the innate and adaptive immune systems is
the PRR TLR-9, which recognizes unmethylated bacterial or viral DNA containing the CpG
motif, as well as the synthetic CpG ODN. The cell types that express TLR9 vary between
species. Many murine cells, including B cells, monocytes and both cDC and pDC express TLR9,
however human expression is far more limited, and mostly seen in pDC and B cells [50]. TLR-9
is located within the endoplasmic reticulum of cells and upon CpG binding, it is translocated to
the endosome, dimerized, and proceeds to recruit MyD88 and trigger a cascade that results in
production of NF-B and the upregulation of pro-inflammatory cytokines TNF-, IL-6, IL-12,
and co-stimulatory molecules such as CD80, CD86, and MHC II [50].
The DC, in its function as a professional APC, is key to the linkage of innate and adaptive
immunity through TLR, and are the most powerful stimulators of naive T cells [51]. DC are
commonly divided into two categories, myeloid (mDC) and plasmacytoid (pDC), based on their
hematopoietic origin, with mDC being derived from a myeloid progenitor and pDC from
lymphoid progenitor cells. The mDC characteristically produce IL-12, and express TLR-2 and
TLR-4, while the pDC are able to produce high levels of IFNand express TLR-7 and TLR-9.
A third category, follicular DC (FDC), are not thought to be of hematopoietic origin, but
resemble DC in their long dendrite-like processes. The mDC and pDC originate within the bone
marrow, and subsequently circulate within the blood before migrating to peripheral tissues such
as the spleen, liver and lung [52]. It has been shown that circulating DCs have strong bone
marrow tropism, and can also migrate back to the bone marrow in a manner dependent on
VCAM-1 and E-selectin, where they are better retained than in the peripheral tissues [52]. Those
DCs that take up antigen (Ag) in the peripheral tissues and then return to the bone marrow are
able to strongly induce proliferation of Ag-specific CD8+ T memory cells (while these cell types
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rarely interact when Ag is not present), presenting a pathway by which DC can link the innate
and adaptive immune responses [52].
The immature DC circulating in the periphery constantly sample the environment, and, due to
their high capacity for endocytosis, take up pathogens [49]. When peripheral immature DC
endocytose a microbial component such as LPS or CpG ODN, their maturation is induced
through the upregulation of MHC class I and II molecules, as well as the expression of several
TLR (such as TLR-1, 2, 4, 5) [47, 52]. This maturation induces upregulation of co-stimulatory
molecules and production of the pro-inflammatory cytokines, and is followed by the migration of
the DC to the draining lymph nodes (LN) where they present the processed antigen to naive T
and B cells and induce the specific adaptive immune response [49]. The maturation of DC by
response to a “danger signal”, such as LPS, is a crucial step as immature DC are poor stimulators
of T cells [53].The particular cytokines produced by the DC have an effect on the type of
immune response generated, with IL-12 production by mDC after TLR4 or TLR9 stimulation
able to promote cell differentiation towards the Th1 type [47]. The activation of TLR on pDC
induces the production of large amounts of IFN, which promotes the differentiation of human
peripheral blood mononuclear cells (PBMC) into DC, and the production of Th1 chemokines as
well as antibodies for protection against viral infection [53]. The Th1 immune response is
MyD88 dependent, while the Th2 type immune response can be generated through the MyD88-
independent pathway [47]. It should be noted that although the various DC subsets express
different TLR, there are some, such TLR7 that are expressed in both types. However the
response to TLR7 activation is different in mDC, which produce IL-12, as compared to pDC,
which produce IFN, indicating that it is not only the type of TLR engaged that directs the
response generated, but also the type of DC being activated [47]. It has also been shown that
small numbers of DCs located in peripheral tissues actually migrate back into the blood, through
which they can travel to non-lymphoid tissues and present Ag to Ag-experienced T cells already
disseminated in the tissue, thus functioning to “boost” the memory response [52]. Due to their
crucial role in inducing Ag-specific T cell responses, DC have frequently been examined in
clinical trials as possible cellular adjuvants, especially for various types of cancer [54, 55]. Other
vaccines use adjuvants that target the DC through intracellular signaling, such as CpG-B ODN,
which signals through TLR-9 to decrease IFN and IFN production in murine mDC and pDC,
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as well as human PBMC [56]. Finally, some adjuvants have been designed to specifically bind to
and act upon the DC itself, through the pre-complexing of Ag to DC-specific antibody (Ab), and
subsequent Ab-mediated targeting of cell surface proteins [57].
Another APC which can function as a bridge between the innate and adaptive immune
response is the M. There are two M phenotypes, M-1 and M-2. It was discovered that in
typically Th1-biased mouse strains such as C57BL/6, M (M-1) stimulated with LPS or IFN-
were more sensitive, and easily activated to produce nitric oxide ( NO) (which inhibits cell
division), while in Th2-biased strains such as BALB/c, LPS stimulated M (M-2) to increase the
metabolism of arginine to produce ornithine (which stimulates cell division) [58, 59]. The
balance between the M-1 and M-2 phenotypes is regulated by M TGF-1, which inhibits the
induction of NO synthase and stimulates arginase. This balance is not dependent on T or B cells
[58]. The dominant phenotype can influence whether a Th1 or Th2 response will occur. When
activated through TLR or scavenger receptors, M also produce IFNand upregulate co-
stimulatory molecules, and thus the ability of the cell to function as an APC is increased [48].
M can also be activated by the innate immune response through recognition of complement
components, antibodies (through Fc receptors), or in response to IFN-, all of which results in an
increased secretion of cytokines which then affect the direction of the adaptive immune response
[48]. 
B cells also link the innate and adaptive immune systems as they express both PRR such as
TLR and antigen-specific B cell receptors (BCR) [60]. B cells are also capable of acting as APC.
TLR pathways are known to affect B-cell activation, proliferation and class-switch
recombination, however the exact factors required remain unknown.  The B cells in the marginal
zone of the spleen are considered more “innate-like” and show greater IgM secretion and plasma
cell differentiation in response to TLR3 and TLR4 ligands than follicular B cells in mice [60]. It
has also been demonstrated that there are higher levels of TLRs on memory B cells as opposed to
naïve cells, and the memory cells are better able to differentiate into plasma cells after further
TLR stimulation, indicating that the activation signals provided to immature B cells by TLR
ligands during the innate immune response may lead to their maturation and increased ability to
function as part of the adaptive immune response [60].
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Finally, the complement system is a main element of the innate immune system, and
consists of over 30 soluble plasma and cell-mediated proteins [61, 62]. It functions to
discriminate between self and non-self, as well as to recognize danger signals, and has several
methods to deal with these issues, including opsonization of pathogens, chemoattraction of
inflammatory cells, and direct lysis of pathogens using the membrane attack complex [61]. It is
now thought that not only does complement function as an innate immune response, it also links
the innate and adaptive responses. Recently it has been shown that the complement component 1
q subcomponent (C1q) component of complement, which binds the Fc receptor on immune
complexes and opsonized pathogens in order to activate the classical complement pathway, is not
only produced by M, but also by DC [61, 62]. It has been shown in mice that C1q is produced
by immature DC, with this production being downregulated after DC maturation, and C1q
knockout mice produce reduced antibody and IFN- T cell responses [61]. Human monocyte
derived DC were activated and matured when exposed to C1q, indicating that this complement
component may function as a link between the immature DC that function within the innate
immune system and the mature DC that activate the adaptive specific immune response [61]. The
C3 component of complement is responsible for opsonizing foreign pathogens and marking them
for destruction by the membrane attack complex. B lypmhocytes are able to bind C3, and the
depletion of this component results in an impaired humoral immune response [62]. It has now
been shown that when the BCR encounters C3 bound antigens, there is a large reduction in the
threshold needed for B cell activation, allowing a stronger humoral immune response [62]. There
is evidence indicating a link between complement activation and the enhancement of T cell
immune responses, with mice treated with a complement component 5a receptor (C5aR)
antiagonist producing fewer antigen specific CD8 T cells after infection, and those that are
deficient in C5aR having reduced responses to infection [62]. The C5aR complement component
has also been shown to have a synergistic effect in combination with TLR4, which further
indicates the likelihood that complement can have a similar function as the PRR in activating the
adaptive immune response [62]. An analogue of the C5aR C-terminal region, called EP67, has
been examined as an adjuvant in both young and elderly mice. It was shown to successfully
function as a complement agonist, engaging and activating APC and enhancing the induction of
Ag-specific humoral and cell-mediated immune responses [63]. Other adjuvants have been found
to function by binding complement proteins, such as CTA1-DD (a mixture of the ADP-
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ribosylating CTA1 subunit of cholera toxin with a d-dimer, derived from Staphylococcus aureus
protein A), which binds to complement receptors on FDC, and subsequently enhances GC
reactions and serum Ab titres [64].
1.4 Adjuvants
1.4.1 Innate Defense Regulator Peptides
These peptides have been known by several names, such as ‘antimicrobial peptides’,
‘cationic host defense peptides’, or, most recently ‘innate defense regulator peptides’. IDR
peptides are a key part of the innate immune system, and are produced by the PMN and epithelial
cells of most vertebrate species [49]. There are two major types of antimicrobial peptides,
defensins and cathelicidins [65]. All IDRP have a cationic charge resulting from the presence of
positive a.a residues such as lysine, tryptophan and arginine, as well as an amphipathic structure
and a large proportion (50% or greater) of hydrophobic residues [66]. Defensins are classified
into two major subfamilies,  and , which are structurally similar, and there is also a third 
subfamily [65]. Defensins all have direct antimicrobial effects, and are able to kill both Gram-
negative and positive bacteria in vitro as well as fungi and some parasites [65]. Defensins kill
pathogens by inserting into and disrupting the cell membrane, resulting in pores which cause
membrane permeability and leakage [65]. -defensins also have anti-viral activity, while -
defensins function by interacting with CC chemokine receptor 6 (CCR6), with both types also
causing mast cell degranulation [65]. Defensins have also been shown to enhance the adaptive
immune response through acting as chemoattractants for immature human DC [65]. Since the
release of defensins is often an innate immune response to infection, the recruitment of immature
DC to the site will allow the adaptive immune response to be effectively generated. The defensin
mBD2 has also been shown to promote the maturation of DC in mice, activating the DC through
a TLR4-dependent pathway [65, 67]. Human  and -defensins are able to bind microbial
antigens with high affinity in both a defensin and antigen-specific manner, which may attenuate
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the production of pro-inflammatory cytokines through alteration of the interaction of the APC
with the antigen [67]. Defensins may also function as adjuvants and facilitate the delivery of
bound antigen to APC while enhancing the immunogenicity of the antigen [67]. The -defensins
known as human neutrophil peptides (HNPs) were shown to enhance ovalbumin (OVA)-specific
humoral serum responses after intra-nasal vaccination, as well as increasing the production of
OVA-specific IFN-, IL-5, IL-6, and IL-10 by CD4+ T cells [68, 69]. For -defensins, human
beta defensin (HBD)-1 and HBD-2 were able to induce significantly higher OVA-specific Ab in
mice after intra-nasal vaccination [69].
Cathelicidins are also found in various species and consist of an N-terminal preregion, a
conserved cathelicidin-like proregion, and a C-terminal microbicidal domain [65]. The only
known cathelicidins generated in humans and mice are called LL-37 (also known as hCAP18)
and cathelin-related antimicrobial peptide (CRAMP), respectively. Cathelicidins function by
acting upon formyl peptide receptor-like 1 (FPRL1)-expressing cells, such as endothelial cells,
and have been shown to be chemotactic for leukocytes such as monocytes, neutrophils and mast
cells [65]. The best characterized cathelicidin is LL-37, which has been shown to have
antimicrobial effects, angiogenic effects in wound healing, as well as enhancing the expression
of chemokines CXCR2 and CCR2 in M, which indirectly assists in immune cell recruitment
[65]. LL-37 is produced by phagocytic leukocytes and epithelial cells, and is found at high levels
at sites of inflammation or infection [70]. It is able to modulate the responses of DC through
enhancement of Th1 type cytokine secretion and upregulation of the DCs endocytic capacity [71,
72]. This immunomodulatory property of the peptide was shown to be independent of its
antimicrobial effects [71]. LL-37 has also been tested in combination with CpG ODN as a cancer
therapy, and was shown to significantly increase the anti-tumour effects of CpG ODN treatment
in a mouse model of ovarian cancer, and increase the proliferation and activation of NK cells
[73]. CRAMP has also been studied as an adjuvant in mice, and was found to induce dose-
dependent humoral and cellular Ag-specific immune responses to OVA [67]. Other IDRP such
as the small bovine derived Bac2A and Indolicidin, have been shown to have similar abilities to
inhibit LPS-induced TNF-secretion in vitro in human monocytes, however the peptides varied
in some of their chemotactic abilities, indicating the diversity of effects that are possible with
these compounds [74]. The immunomodulatory abilities of various IDRP result in their being
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examined for use as adjuvants or anti-infective therapeutics. The peptide IDR-1, which is not
directly antimicrobial, was shown to be protective against infection with both Gram-negative and
positive bacteria when administered from 48h prior to 6h after infection, with this protection
being mediated by monocytes and M[66, 75]. The synthethic peptide IDR-1002, a derivative of
Bac2a, shows promise as a possible adjuvant due to its ability to induce chemokines in human
PBMC [76]. This peptide has also been shown to be effective at leukocyte recruitment and was
protective against bacterial infection due to the combination of chemokine induction and
neutrophil and monocyte recruitment to the infection site [76]. Another example of a cathelicidin
being considered as an adjuvant is salmon cathelicidin (asCATH), which has been shown to
transiently and specifically stimulate IL-8 production in order to recruit immune cells to the site
of infection, and has been suggested as a possible adjuvant for aquaculture [77].
There is evidence that TLR are involved in IDR peptide secretion and thus in the
antimicrobial effect of the peptides [47]. LL-37 has also been shown to modulate the
inflammatory response to TLR agonists [78]. The fact that new high-throughput methods of
IDRP generation have been developed further adds to their attractiveness as adjuvants, as the
cost of production has been significantly lowered [79]. Other examples of antimicrobial peptides
and proteins being studied for their adjuvant capabilities include lactoferrin and melittin [67, 80].
1.4.2  CpG Oligodeoxynucleotides
CpG ODN are synthetic mimics of unmethylated bacterial DNA sequences, and have
very well characterized and strong adjuvant properties. They are recognized as a PAMP by the
PRR TLR9, which is expressed intracellularly in B cells and pDC in humans, and in mDC and
M in mice [47, 81]. CpG ODN are internalized through non-specific uptake into the cell, and
subsequently colocalize with TLR9 in the endosome, resulting in the activation of a MyD88-
dependent pathway that releases NF-B [47, 81]. They can be a strong activator of DC
production of IL-12, which polarizes T cells in the Th1 direction, and thus CpG ODN are well-
known as Th1 promoting adjuvants [47]. There are three classes of CpG ODN, referred to as A,
B, and C-Class, which vary in the effects produced. The A-Class function through activation of
pDC cells in humans and result in strong IFN production, B-Class stimulates the direct
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activation of B and NK cells, and C-Class combines the effects of both of the previous classes
[81, 82]. A recent comparison of several motifs from each class in vivo in mice indicated that,
when used as adjuvants, B and C-Class CpG ODN were able to induce strong Th-1 biased
antibody, CD4+ and CD8+ responses, while the A-Class CpG ODN were unable to affect the
IgG1/IgG2a antibody ratio and did not elicit Ag-specific IFN- secreting CD4+ and CD8+ T cells
[83]. All three classes function through TLR9 activation, and all stimulate the secretion of IL-6
in human PBMCs [81]. CpG have been tested and shown to be strong immunostimulants in an
enormous variety of species, including but not limited to; mice, cattle, sheep, nonhuman
primates, humans, dogs, cats and fish [84]. They are potent mucosal adjuvants, and can be used
as a stand-alone treatment of respiratory infections in mice, since when given intra-nasally they
quickly induce a transient cytokine response which allows DC and NK cells to be activated and
recruited to the lung [85]. CpG ODN have also been tested in clinical trials in humans and are
able to enhance the avidity maturation process when included with a Hepatitis B vaccine,
resulting in a larger number of high avidity antibodies to the vaccine antigen [86, 87]. CpG ODN
have been tested in humans in many types of vaccines, including, but not limited to, those
against Hepatitis B Virus, Influenza, and Plasmodium falciparum (Malaria), resulting in strong
immune responses and an acceptable safety profile [88-91]. There are many more vaccines
containing CpG ODN that have been tested in animal models, including those against HIV,
human papilloma virus, and Mycobacterium tuberculosis (tuberculosis) [92-94]. The method of
formulation and delivery of CpG can enhance the innate and adaptive immune responses
resulting after vaccination [84]. For example, the covalent linkage of CpG ODN to antigen has
been shown to increase the immune responses even further, and it has been suggested that the
immune response to CpG ODN is dependent on the administration route [87]. In mucosally
immunized mice, spleen cells produced strong IFNas opposed to IL-4 upon antigen re-
stimulation [82]. It has also been shown in mice that immunization with CpG ODN results in
strong levels of IFN- production and IL-12 in the serum [84].
CpG ODN show promise as adjuvants for neonatal vaccination, and addition of CpG
ODN to neonatal vaccines has been shown to successfully enhance the IFN- response to adult
levels in some cases [36]. The use of CpG ODN as a vaccine adjuvant in neonatal mice and
piglets has also been shown to promote the switch from a Th2 towards a Th1 type of response
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[87]. Although CpG ODN are strongly immunostimulatory, they have a very good safety profile
at therapeutic doses, although toxicity has been seen in cases of daily high dose injections [87].
1.4.3  Polyphosphazenes
Polyphosphazenes (PP) are biodegradable polymers made up of an inorganic alternating
phosphorus-nitrogen backbone with additional reactive side groups. They are linear polymers
with a high molecular weight and there can be two side groups attached to each phosphorus atom
[95]. The versatility of PP is due to the large number of various side groups that can be attached,
including hydrophilic groups such as amino acid esters, lactate and imidazole, or hydrophobic
ones including aryloxy and fluoroalkoxy groups, allowing the extreme fine tuning of the polymer
backbone, and the fact that when degraded, the resulting products are usually nontoxic [95-97].
PP can be designed to degrade at a biological pH, or at certain temperatures, which allows them
to be used as a biodegradable matrix, with great potential for use in vaccines, controlled drug
delivery, or as tissue engineering scaffolds [95, 97]. They can be designed to vary in size,
stability, and ability to load protein, and this flexibility gives them a huge range of possible
applications [96]. PP have been found to function as potent immunostimulants when conjugated
to antigenic proteins even in a noncovalent manner [96]. It has been shown that when the
polyphosphazene Poly[di(carboxylatophenoxy)phosphazene] (PCPP) was mixed with antigen,
water-soluble noncovalent PP:Ag complexes were formed. It is thought that these are able to
target the lymphocyte cell surface and cluster together the membrane proteins, which results in
the stimulation of intracellular ionic fluxes, followed by ATPase activation and an enhancement
of the immune response [96]. PCPP has also been tested for use as a mucosal adjuvant for
intranasal immunization against respiratory pathogens, and was shown to be an effective inducer
of sIgA and IgG antibody production in the mucosal secretions and serum of immunized mice,
and was able to protect against intranasal challenge with infectious agents including B. pertussis
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and Streptococcus pneumoniae [98]. The immune responses seen were of a mixed Th1 and Th2
type, with strong IgG2a and IgG1 titres along with IFN- and IL-4 production [98].The
polyphosphazene Poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP) has also been
characterized and compared to PCPP as a vaccine adjuvant in mice, and it has been found that it
too is capable of inducing strong antigen specific immune responses [99]. Immunization with
PCEP was shown to induce the production of IFN- and IL-4, as well as resulting in superior
amounts of IFN- and IgG2a production as compared to PCPP, indicating that it may be able to
promote a more Th1 type immune response than PCPP, although it does induce both Th1 and
Th2 type responses [99]. When compared to the most commonly used vaccine adjuvant alum,
both PCPP and PCEP were able to induce significantly superior IgG2a antibody responses, as
alum resulted in a mostly IgG1 or Th2 type response, suggesting that the PP may be used to
modulate the immune response towards a more balanced or mixed Th1/Th2 response [99, 100].
Lastly, the ability to formulate PP including PCPP and PCEP into microparticles is a
promising strategy for use in vaccine antigen and adjuvant delivery [100]. Microparticles are
able to be phagocytosed by M and DC, inside which the antigen can be released and more
efficiently presented to the antigen-specific cells of the adaptive immune response [100]. The
particles, usually less than 10m in size, are also are able to create a depot effect, allowing
antigen to be masked from interfering MAb, as well as to maintain the antigen presence at the
site of injection for a longer period, which allows efficient T-cell responses to be induced [100].
1.4.4 Combination Adjuvants
Through combining different adjuvants, one can try to elicit the best possible immune
responses to vaccination. Ideally, synergistic effects between adjuvants can improve the immune
responses several fold over use of any of the components alone. There are many combination
adjuvants that are currently being examined for use in vaccines. A good example of this is the
adjuvant system 04(AS04) adjuvant. AS04 contains monophosphoryl lipid A (MPL) adsorbed
onto alum, with MPL being the only TLR ligand currently approved for use in human vaccines.
MPL signals through TLR-4, as it is a derivative of the Lipid A molecule found on the LPS of
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Gram-negative bacteria, while alum has recently been proven to signal through the Nalp3 NOD-
like receptor [101]. There are MPL adjuvanted vaccines currently available for Hepatitis B
(Fendrix®) as well as Human Papilloma Virus (Cervarix®), and MPL has been studied in
clinical trials of several cancer vaccines (both alone and in combination with other adjuvants)
[102, 103]. Use of either alum or MPL alone only stimulates a mild immune response to the
HPV vaccine, but in combination, strong immune responses result [104]. MPL has also been
examined in mice in combination with the innate antimicrobial protein lactoferrin as an adjuvant
complex, and was an efficient stimulator of both humoral, and cellular immune responses [80].
There are few adjuvants currently approved for human use, including alum, MPL, AS04, MF59,
adjuvant system 03 (AS03), and immunopotentiating reconstituted influenza virosomes (IRIVs)
[105]. The first adjuvant licensed for use in humans after alum was MF59™, an adjuvant
consisting of a squalene in oil emulsion, that is used in the Fluad™ and Focetria™ vaccines
against H1N1, and has been shown to stimulate production of CD4+ memory cells [106-108].
When tested in combination with microparticles and an HIV protein, the combined
microparticles in MF59 adjuvant combination was able to induce significantly greater antibody
responses as compared to the separate adjuvants in mice and baboons [109]. A possible
mechanism of action for MF59™ is that microdroplets of the emulsion are taken up by M,
which then secrete cytokines to enhance the immune response [110]. Squalene is also a key
ingredient in AS03, the combination adjuvant licensed for use in humans, which is composed of
squalene, another immunostimulatory oil called DL--tocopherol (a vitamin E derivative), and
the surfactant polysorbate 80. AS03 is also included in the human H1N1 type influenza vaccines
Pandemrix™ and Arepanrix™, as well as in the H5N1 Prepandrix™ vaccine [107, 111]. The
H1N1 vaccines adjuvanted with either AS03 or MF59™ were able to induce strong antibody
responses in adult vaccinated populations, as determined through serum hemagglutination-
inhibition assays [112, 113]. In addition, an AS03-adjuvanted H1N1 vaccine has recently been
shown to be highly immunogenic in children 6-35 months of age, with an acceptable
reactogenicity profile [114].
Microparticles have been studied as delivery vehicles for CpG ODN adjuvants, and are
able to induce strong immune responses, especially when antigen is encapsulated into the
microparticle along with the CpG ODN, with these responses being greater than those seen with
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the adjuvant components delivered separately [84]. When combined with the encapsulated
antigen OVA, a stronger cytotoxic T-lymphocyte (CTL) response and increased cross-priming
was seen in mice after vaccination as compared to when the components were given separately
[115]. Simple co-formulation of CpG ODN with PP (not in microparticle form) has also been
shown to have a synergistic effect on the serum IgG titre and neutralizing antibody titre of mice
immunized against bovine respiratory syncytial virus, as compared to the use of each adjuvant
separately [116].
Liposomes have also been used to encapsulate CpG ODN and this has been shown to
enhance the effects of the adjuvant in many ways, including protection from nuclease activity, a
decrease in the rate of adjuvant distribution, and facilitation of CpG ODN delivery to the
cytoplasm [84]. Microparticles have also been studied as delivery vehicles for CpG ODN, and
are able to induce strong immune responses, especially when antigen is encapsulated into the
microparticle along with the CpG ODN, with these responses being greater than those seen with
the adjuvant components delivered separately [84]. IRIVs are proteoliposomes made of surface
glycoproteins from the influenza strain H1N1, and have been used as adjuvants in the human
hepatitis A vaccine Epaxal™ [110, 111]. The virosomes can be loaded with Ag, with the
hemagglutinin protein of the influenza virus targeting the virosome to the APC, which
subsequently endocytoses and intracellularly processes it, finally expressing the vaccine Ag
through MHC I and II molecules [110, 117]. IRIVs are also currently in clinical trials for use in
vaccines against malaria [118].
When used in combination, the IDRP LL-37 has been shown to promote the sensing of
CpG ODN in human B cells and pDC in vitro, with 20 times less CpG ODN required to create a
reaction in the presence of the peptide [119]. When the synthetic IDRP HH-2 was complexed
with a CpG ODN and used with a pertussis toxoid antigen, the combined adjuvant was found to
have a synergistic effect on induction of the chemokine MCP-1, as well as on the upregulation of
the co-stimulatory molecule CD80 on monocytes and mDC [120]. Production of the IgG1, IgG2a
and IgGA antibody titres was also strongly induced with the combination of adjuvants [120].
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Other important adjuvants currently being studied both alone and in various combinations
currently being studied include immune stimulating complexes (ISCOM, containing the saponin
Quil-A), the purified plant extract QS-21, imiquimod, and AS02 (containing MPLTM and QS-21
in an oil-in-water emulsion), as well as various combinations of TLR agonists. It has been found
that simultaneously stimulating several TLR during vaccination against Respiratory Syncytial
Virus was able to improve antibody affinity maturation in mice, and the resulting antibodies
were better able to neutralize the pathogen [121]. There have been synergistic increases in
cytokine production when multiple TLR stimulation of different pathways has been used to
stimulate DC [104].
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CHAPTER 2: RATIONALE, HYPOTHESIS AND OVERALL OBJECTIVES
2.1 Hypothesis
Co-formulation of PTd with CpG ODN, IDRP, and PP, promotes a long-lasting
protective balanced or Th1-biased response against Bordetella pertussis in neonatal mice
following vaccination.
2.2 Overall Objectives
1. Characterize the magnitude and isotype profile of the humoral immune response in
BALB/c mice vaccinated as adults with PTd and various adjuvant formulations.
2. Characterize the magnitude and isotype profile of the humoral response of BALB/c mice
vaccinated as neonates with PTd and various adjuvant formulations
3. Further characterize the quality of the immune response in vaccinated BALB/c mice
through examination of the cytokine profile, the duration of immunity, protection against
challenge infection, and comparison of single versus two-dose immunizations.
4. Characterize the adjuvant platform further by examining safety and cell recruitment, as
well as the versatility of the adjuvant platform with other antigens.
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CHAPTER 3: ANTIBODY RESPONSES IN ADULT AND NEONATAL MICE TO
IMMUNIZATION WITH NOVEL BORDETELLA PERTUSSIS VACCINE
FORMULATIONS
3.1 Introduction
Whooping cough is an acute, highly communicable infection caused by the Gram-negative
bacterium Bordetella pertussis. It is a major childhood illness in the developing world and even
in several industrialized nations [11, 14, 122]. Pertussis causes significant morbidity and
mortality mostly in infants and young children, who are either too young to have been vaccinated
(< two months old), or who have not received their full series of vaccinations [11, 14, 123].
Although it is reported that >80% of people in industrialized nations have been vaccinated
against pertussis, there has been a resurgence of the disease within the past two decades [14, 122,
123].
B. pertussis is generally considered to be an extracellular pathogen that localizes at the epithelial
cell surface and thus it was previously believed that humoral immunity and a Th2-type response
would mediate protection, as is usually the case for extracellular bacteria [6]. Although
antibodies can be protective against infection, as shown by passive antibody transfer,
experiments in mice have shown that circulating antibodies are not necessary for maintenance of
vaccine-mediated immunity [26, 27]. Since B. pertussis is also able to invade human and mouse
lung macrophages, full clearance of this pathogen requires an additional strong cell-mediated
immune response (CMI), with antibody alone being insufficient [6, 24, 26, 27].  Studies of
pertussis infection in human infants and mice indicate that a strong Th-1 response, specifically
mediated by IFN-, is required to resolve infections [22, 25, 27]. Polarizing the T-cell response
after vaccination towards a Th-1 type response has been shown to improve the effectiveness of
acellular pertussis vaccines [27]. Indeed, respiratory-challenge protection has been shown in the
absence of a detectable antibody response, but is correlated with a strong Th-1 response [26].
The neonatal immune response is functionally skewed towards a Th-2 type bias, [36, 37], in
part due to the repression of Th-1 responses in the mother and fetus during pregnancy, and
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compromised antigen presentation. This immune bias can preclude successful infant
immunization when a pathogen, such as pertussis, requires the induction of a balanced or Th1-
type immune response through vaccination.  Recent studies in mice have indicated that use of
appropriate adjuvants, such as simultaneous stimulation of multiple Toll-like receptors (TLR),
can augment the immune response in neonates and may compensate for a suboptimal immune
system [124]. Thus, to achieve the best possible immune response to vaccination in neonates,
multiple adjuvants working synergistically through multiple mechanisms may be required. In the
present study we have evaluated a combination of novel adjuvants based on three distinct types
of immunomodulators, which together promote a more balanced or Th-1 type response.
Cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODN) are intracellular TLR-9
ligands and potent activators of the innate and adaptive immune systems of many species
(reviewed in [82]). CpG ODNs promote a Th-1 biased pro-inflammatory response with increased
IL-1, IL-6, IL-18, IFN- and IL-12 cytokine production; these then induce the maturation of
APCs (reviewed in [82, 87]). CpG ODN have been used as adjuvants to promote switching from
a Th-2 response to a Th-1 response in neonatal mice[87]. Since TLR signalling and activation is
necessary for DC maturation and B cell activation, marked effects on antibody production would
also be expected, making CpG ODN an excellent candidate adjuvant for a vaccine aimed at
shifting the immune response towards the Th-1 direction [84].
Polyphosphazenes (PPs) are synthetic polymers with an inorganic backbone of alternating
phosphorus (P) and nitrogen (N) atoms and two side groups attached to each P (reviewed in
[95]). PPs can form microspheres to encapsulate possible vaccine antigens [96, 97]. Two PPs in
particular have been frequently examined as potential adjuvants, polyphosphazene
polyelectrolyte, poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) and
poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP). PCEP is a strong adjuvant that,
when compared with PCPP in a murine model, was found to be an even better enhancer of
antigen-specific Th-1 and Th-2 immune responses. PCEP modified the immune response from a
Th-2 bias to a mixed Th-1/Th-2 response, with both PPs being vastly more potent adjuvants than
alum [99].
Cationic innate defence regulator peptides (IDRP) are naturally-occurring innate host defence
molecules found in animals, insects, and plants. Although originally studied for their (often-
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weak) direct antimicrobial activities, they have a number of immunomodulatory properties.
These include recruitment and selective activation of immune cells including dendritic cells (DC)
through mechanisms independent of TLRs, synergy with CpG ODNs, and an ability to protect
against a variety of bacteria in mouse infection models (reviewed in [125, 126])[78]. IDRPs are
evolutionarily conserved and involved in the interface between innate and adaptive immunity
[71, 72]. At physiological concentrations, IDRPs can induce the chemotaxis of immune effector
cells, through chemokine induction or leukocyte recruitment, to the site of infection, allowing
innate, then adaptive immune responses to be generated [74-76, 127].  Evidence exists that
IDRPs such as cathelicidins and defensins can function as potent adjuvants and promote antigen-
specific cellular and humoral immune responses in murine models [65].
The present study was undertaken to determine whether a novel combination of vaccine
adjuvants can shift the immune response to B. pertussis in both adult and neonatal mice towards
a balanced or more Th-1 type response. The results suggest that this vaccine adjuvant technology
can be viewed as a platform for future neonatal vaccines directed against pathogens that require a
strong cell-mediated immune response for full clearance.
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3.2 Materials and Methods
3.2.1. Animals
Adult male and female BALB/c mice were obtained from Charles River Laboratories
(Wilmington, MA). All mice were housed and cared for in the Animal Care facilities at VIDO,
University of Saskatchewan (Saskatoon, SK). 8-week old females were used for all adult mouse
studies, and mice were bred in the Animal Care facilities at VIDO, University of Saskatchewan,
to obtain neonatal mice. Neonates were immunized at 7 days and housed with their dams until
weaning at four weeks of age. Mice were selected at random for cage assignments, with each
cage housing mice from at least two different groups. When sampling, mice were selected at
random in equal numbers from each cage housing that group. Animal technicians were not blind
to the group assignment of mice, however those performing the experiment were. All animal
experiments followed the guidelines of the University of Saskatchewan and the Canadian
Council for Animal Care. All animal experiments were performed in agreement with the
guidelines proposed by the University of Saskatchewan and the Canadian Council for Animal
Care.
3.2.2. Immunization of Mice
Adult mice were immunized subcutaneously between the shoulder blades with either 50 µl or
100 µl of vaccine, or sterile phosphate-buffered saline (PBS) (Gibco, Invitrogen; Carlsblad, CA),
and given a secondary immunization in the same manner after four weeks unless otherwise
indicated. Neonatal mice also received 50 l of the respective formulations or sterile PBS
subcutaneously between the shoulder blades and were boosted in the same manner after four
weeks. Experimental groups requiring pre-complexing of the IDRP and CpG ODN adjuvants had
IDRP and CpG ODN components co-incubated in 1.5 ml Eppendorf tubes (VWR; West Chester,
PA) at 37ºC in a block heater for 30 minutes prior to the addition of any other vaccine
components.
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3.2.3 Vaccine Components
Genetically detoxified PTd was provided by Novartis (formerly Chiron) (Siena, Italy) [128].
Received batches were centrifuged at 1350 g for 10 min before being stored at -20°C in aliquots.
Frozen aliquots were thawed at room temperature and then centrifuged at 1350 g for 10 min. The
supernatents were removed and subsequently stored at 4°C for use in the vaccine formulations.
Three IDRPs, IDR-HH2, IDR-HH18, and IDR-HH1002, were synthesized using a standard solid
phase FMOC method [76]. De-protected IDRPs were cleaved from the resin and purified by
reverse phase HPLC prior to lyophilization. Lyophilized IDRPs were resuspended in de-ionized
water prior to dilution in PBS for use. CpG ODN were purchased from Coley Pharmaceuticals
(now Pfizer). The polyphosphazenes PCEP (VIDO-EP#3) and PCPP (VIDO-PP#4) were
synthesized as described previously [99] with minor modifications. The synthesis was performed
by the Idaho National Laboratory (Idaho Falls, ID), under the supervision of Dr. John Klaehn.
Polyphosphazenes were received in lyophilized form and stored at 4°C in the dark, then
dissolved for use in Dulbecco’s PBS (1.54 mM KH2PO4, 155.17 mM NaCl, 2.71 mM Na2HPO4-
7H2O, Sigma-Aldrich, MO) by gentle shaking for 36 hours at room temperature (RT). After
resuspension, polyphosphazenes were stored in aliquots at RT in the dark.
Quadracel®™ was purchased from Sanofi Pasteur (Toronto, ON). The human dosage of 0.5 ml,
contains 15 Lf-units of Diphtheria toxoid, 5 Lf Tetanus toxoid, acellular pertussis [20 g
chemically-detoxified pertussis toxoid (PT), 20 g filamentous haemagglutinin (FHA), 3 g
pertactin (PRN), 5 g fimbriae types 2 and 3 (FIM)], inactivated poliomyelitis vaccine (IPV) 40
D-antigen units type 1 (Mahoney), 8 D-antigen units type 2 (MEF-1) and 32 D-antigen units type
3 (Saukett)] with 1.5 mg aluminum phosphate as adjuvant. For immunization of mice, the
volume administered was adjusted to contain a dose of chemically-detoxified PT identical to that
of the genetically-detoxified PTd in the novel vaccine formulations studied here.
3.2.4. ELISA analysis of PTd-specific Abs
Blood was collected through tail bleeding at two week intervals, starting at zero weeks (at the
time of the initial immunization) for adults, and four weeks post-initial immunization for
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neonates. Serum was then collected by centrifugation of the blood in a microcentrifuge at 5940 g
for five minutes, and this was used to perform ELISAs.
Polystyrene microtiter plates (Immulon 2 HB; Thermo, Milford, MA) were coated overnight at
4ºC with 0.25 g/ml of PTd antigen in coating buffer (15.0 mM Na2CO3 and 34.88 mM
NaHCO3). The plates were then incubated for two hours with serially diluted sera. Goat anti-
mouse biotin conjugated detection antibodies specific for mouse IgG1 and IgG2a (Caltag
Laboratories, Burlingame, CA; 1/10,000 dilution) were used to examine the PTd-specific
antibody titres within the sera. Streptavidin Alkaline Phosphatase (Jackson ImmunoResearch;
West Grove, PA; 1/5000 dilution, starting concentration 500 g/mL) was used to amplify the
reaction, and p-nitrophenyl phosphate (Sigma-Aldrich, St.Louis, MO; dilution 1 mg/ml) was
used as a substrate. Samples were analysed using a spectrophotometer (Bio-Rad iMark
Microplate Reader; Philadelphia, PA) at 405 nm with a reference of 490 nm.
3.2.5. Statistics
Data were analyzed for normal distribution and significance using the STATA program version
10 for Windows (StataCorp LP, College Station, TX). Data was assessed for normality using the
Shapiro-Wilk test. In order to achieve a normal distribution of data, the sums of all of the
repeated measures were taken, and these sums subsequently ranked. The resulting ranked data
passed the normality test (p > 0.05). One-way ANOVA was used on the normally distributed
data to determine the presence of a significant difference between groups, followed by Scheffe’s
test to separate the means and identify which groups were significantly different. A p-value of p
< 0.05 was considered statistically significant.
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3.3 Results
3.3.1. Selection of adjuvant candidates
Class-A (CpG 8954), Class-B (10103), and a Class-C (10101) CpG ODN were tested to
determine which was best able to stimulate a Th-1 type immune response in combination with
PTd. Adult mice were immunized at time zero and 4 weeks with 0.05 g of PTd plus each of
these CpG ODNs, and at 2-week intervals, the serum IgG1 and IgG2a serum titres were
compared. Immunization with 10 g of each class of CpG ODN resulted in a statistically
significant increase in IgG2a titres (indicative of a Th1 response) as compared to either PTd
alone or 10 g of the corresponding GC 2243 (for Class-A) or GC 2137 (for Class-B/C)
backbone control ODN (Fig 3.1A). However, no significant difference was observed in the IgG1
titres (indicative of a Th2 response) between the CpG groups compared to each other or to PTd
alone (data not shown). Class-C CpG 10101 ODN was selected for inclusion in the vaccine
adjuvants described here, as its mechanism of action is reported to combine the qualities of both
Class-A and Class-B CpG ODN [81].
The polyphosphazenes PCEP (VIDO-EP#3) and PCPP (VIDO-PP#4), were selected for
testing. Adult mice were immunized with 0.10 g of PTd and either 50 g or 100 g of each
polyphosphazene, with or without 10 g of the selected CpG ODN, and the serum IgG1 and
IgG2a titres were compared. Both the 50 g/mouse and 100 g/mouse doses of VIDO-EP#3, in
combination with CpG C ODN and PTd, were found to induce higher IgG2a titres than VIDO-
PP#4 and CpG C, however, these increases were not statistically significant. We observed a 500-
fold increase in IgG2a titre, as compared to PTd antigen alone, after boosting with VIDO-EP#3
at four weeks. A statistically significant difference in IgG2a titres was observed in mice
immunized with PTd plus 50 g or 100 g VIDO-EP#3 as compared to mice immunized with
PTd plus 50 g VIDO-PP#4 (Fig 3.1B). No statistically significant differences in the IgG2a
titres, as compared to PTd alone, occurred after immunization with either dose of VIDO-PP#4.
The IgG1 titres showed no significant differences between the two doses of the two
polyphosphazenes. Mice vaccinated with PTd antigen alone failed to produce statistically
significant PTd-specific IgG2a titres as compared to unvaccinated mice over the entire course of
the experiment. However, these mice did display a significant increase in IgG1 response. When
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CpG was included with the polyphosphazenes in the adjuvant formulation, we observed a
statistically significant increase in IgG2a titres as compared to PTd alone; however, there were
other differences noted between the four PP plus CpG-adjuvanted groups. None of the mice
vaccinated with 50 g/mouse VIDO-PP#4, PTd and CpG ODN produced a significant IgG2a
response. When the dose was increased to 100 g/mouse VIDO-PP#4 (still including CpG),
three mice failed to respond post-vaccination, and four mice responded after 8 weeks or longer,
instead of the usual four to six weeks. In contrast, all except one mouse vaccinated with 50
g/mouse VIDO-EP#3, PTd, plus CpG ODN produced an IgG2a response, and only two mice
vaccinated with 100 g VIDO-EP#3 (plus PTd and CpG ODN) failed to produce detectable
IgG2a. Thus VIDO-EP#3 as a vaccine adjuvant appeared to be a more consistent stimulator of
the IgG2a response, and was selected for further formulations.
Two IDRPs, IDR-HH2 (VQLRIRVAVIRA-NH2) and IDR-HH18 (IWVIWRR-NH2) were
synthesized and tested. Adult mice were immunized with 0.1 g of PTd together with 75 g or
150 g (3.75 mg/kg or 7.50 mg/kg respectively) of IDR-HH2 or IDR-HH18, were boosted in the
same manner after 4 weeks, and the IgG1 and IgG2a serum responses were analyzed.
Vaccination with each IDRP and PTd at 75 g/mouse or 150 g /mouse doses resulted in no
detectable IgG2a response. When the IDRPs were combined with a 10 g/mouse dose of CpG C
ODN and PTd, a statistically significant IgG2a response was observed in mice immunized with
75 g/mouse of IDR-HH18 as compared to mice immunized with PTd only (Fig 3.1C).
Vaccination with 150 g/mouse of this IDRP resulted in the ablation of the IgG2a response.
The lower dose of IDR-HH18 combined with CpG ODN was the only IDRP group tested that
was statistically different from the PTd antigen alone. Thus, there appeared to be an inverse dose
effect, with lower doses of IDRP able to increase the IgG2a titres better than higher doses.
Vaccines formulated with IDR-HH2 resulted in no detectable IgG2a response, and addition of
CpG C ODN did not improve the results. Upon measuring the IgG1 titres, we observed that
either IDRP alone resulted in a greater increase in IgG1 titres as compared to either IDRP in
combination with CpG C (data not shown). However, once again lower doses appeared to
perform better in the IDRP and CpG C combination groups. Due to the IgG2a results, as well its
potential effects on cellular recruitment and cytokine levels, IDR-HH18 was selected as the
IDRP for continued testing.
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Figure 3.1 PTd-specific serum IgG2a Ab responses to immunization with various adjuvants.
Adult BALB/c mice (n = 8 or 10 mice per group) were immunized with PTd antigen alone, PBS, or antigen
combined with various dosages of  CpG ODN, IDRP, or PP at 8 weeks of age. An identical secondary immunization
was given at 4 weeks. Sera were collected immediately prior to initial immunization and every 2 weeks thereafter
for 10 weeks. Median titres are shown. A) Statistically significant differences occurred between each class of CpG
ODN relative to PTd alone (p<0.05) treated mice. B) Statistically significant differences occurred between CpG
ODN and PTd alone (p<0.001), 50 g or 100 g of VIDO-EP#3 and PTd alone (p<0.005), and also between 50 g
of VIDO-PP4 as compared to 50 g or 100 g of VIDO-EP#3 (p<0.001). C) Statistically significant differences only
occurred between CpG ODN combined with 75 g IDR-HH18 as compared to PTd alone (p<0.05) treated mice.
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3.3.2. Testing the Combined Adjuvant Platform in Adult Mice
After the selection of each of the components, a vaccine combination using the adjuvant
platform was developed. It had been found in vitro that when CpG ODN was added to IDRPs, a
precipitate complex was formed that was able to enhance chemokine production in vitro, as well
as to increase mucosal and systemic responses in vivo [120]. Thus, vaccine groups were included
to confirm the ability of this complexing of components to increase immune responses in vivo.
Vaccine formulations consisted of 0.1 g PTd, 10 g CpG ODN, 50 g VIDO-EP#3, and either
10 g or 75 g of IDR-HH18. To create the complexed precipitate, CpG C and IDR-HH18 were
pre-combined and heated at 37°C for 30 min. Non-complexed groups had CpG C and IDR-HH18
kept separate until immediately prior to injection. Adult mice were immunized and boosted with
variations of the adjuvant platform combination and the serum IgG1 and IgG2a titres were
compared (Fig.3.2A & B).
A large increase in serum IgG2a titres was observed in mice immunized and boosted with the
adjuvant platform formulations as compared to PTd antigen alone (Fig. 3.2A). An earlier,
stronger IgG2a response was observed when the adjuvants were complexed prior to vaccination.
The noted difference in response was statistically significant (p< 0.05) between the two groups
containing a 75 g dose of IDRP. Even when the IDRP dose was lowered to 10 g/mouse,
antibody titres rose earlier and higher in the complexed adjuvant platform group as compared to
the non-complexed group.
The IgG1 serum response after vaccination showed a similar trend to the IgG2a (Fig. 3.2B).
There was a notably earlier and significantly greater IgG1 response when the adjuvants were
included in the vaccine, as compared to antigen alone. There was also a significant difference in
IgG1 titres seen between the complexed and non-complexed adjuvant platform groups; however,
there was no difference seen between the complexed groups containing the higher 75 g/mouse
dose of IDRP, and the lower 10 g/mouse dose. There was also a notable IgG1 response to mice
immunized with PTd alone, similar in strength to that of the non-complexed adjuvant platform
group, which is similar to that seen in other experiments, as immunization with PTd alone tends
to result in an IgG1 response as opposed to IgG2a.
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When comparing the IgG2a responses, we observed several non-responders in the PTd only
group (Table 3.1). Three mice in this PTd group that did not produce detectable IgG2a also failed
to produce an IgG1 response to the antigen. In contrast, mice from the higher dose 75 g/mouse
IDRP group complexed with CpG ODN all showed a measurable IgG2a response to vaccination,
with no late responders. All of these mice also had an IgG1 response. In the non-complexed
adjuvant platform group containing 75 g/mouse of IDRP, there were two IgG2a non-responder
mice, and three late-responders. The adjuvant platform group containing 10 g of IDRP
complexed with CpG ODN contained three IgG2a non-responders. These three IgG2a non-
responders were also IgG1 late-responders.
Table 3.1 Individual IgG2a antibody responses & antibody kinetics post-vaccination for
Fig 3.2a
Vaccine Groupa Non-Rb Late-Rc Avg-Rd Mouse Total
PTd (0.10g) 7 2 1 10
PTd (0.10g) + CpG C (10g) + IDR-HH18 (10g) + VIDO-EP#3 (50g)
-complexed 3 1e 6 10
PTd (0.10g) + CpG C (10g) + IDR-HH18 (75g) + VIDO-EP#3 (50g)
-complexed - - 10 10
PTd (0.10g) + CpG C (10g) + IDR-HH18 (75g) + VIDO-EP#3 (50g)
- not complexed 2 3 5 10
aVaccine components of group, antibody titre results shown in Figure 3.2a.
b Non-R = Number of "non-responding mice", a mouse that has non detectable antibody titre over the
course of the experiment
c Late-R = Number of "late-responding mice", a mouse that has no detectable antibody titre until 8 weeks
post-immunization or later
d Avg-R = Number of "average-responding mice", a mouse that has detectable antibody titre prior to
8 weeks post-immunization
e 1 mouse was found dead in this group
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Figure 3.2 PTd-specific serum Ab responses to immunization with various adjuvant platform combinations.
Adult BALB/c mice (n = 10 mice per group) were immunized with either 0.1g PTd antigen alone (▲), PBS (●),
PTd (0.1g)+ CpG C(10g)+ IDR-HH18(10g)+ VIDO-EP#3(50g), with the IDRP & CpG components
complexed (■), PTd (0.1g)+ CpG C(10g)+ IDR-HH18(75g)+ VIDO-EP#3(50g), with the IDRP & CpG
components complexed (▼), or PTd (0.1g)+ CpG C(10g)+ IDR-HH18(75g)+ VIDO-EP#3(50g), with the
IDRP & CpG components not complexed (x), at 8 weeks of age. An identical secondary immunization was given at
4 weeks. Sera were collected immediately prior to the initial immunization and every 2 weeks thereafter for 10
weeks. Median titres are shown. A) Statistically significant IgG2a differences occurred between the adjuvant
platform containing 75g IDR-HH18 (complexed with CpG ODN) relative to PTd (p<0.005) treated mice and
between the non-complexed and complexed adjuvant platforms containing 75 IDR-HH18 (p<0.05). B) Statistically
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significant IgG1 differences occurred between the adjuvant platform containing 75 g IDR-HH18 (complexed with
CpG ODN) relative to PTd (p<0.005) treated mice and the non-complexed adjuvant formulation (p<0.005).
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3.3.3. Triple Adjuvant Combination in BALB/c Neonatal Mice
Seven-day old mice were used in our neonatal experiments. This age has been shown to
correlate best with the human neonate’s immune system [36, 37]. BALB/c pups were
immunized, and the serum IgG2a and IgG1 titres monitored over time (Fig. 3.3A & B). A higher
dose of PTd was used for vaccination in the neonatal model to compensate for the reduced ability
of the immature immune system to respond to the antigen, and the dosages of other vaccine
components used were adjusted for the smaller weight of the pups in comparison to adult mice.
Vaccine formulations consisted of 1.0 g PTd, 2.37 g CpG ODN, 2.37 g VIDO-EP#3 and
35.55 g of IDR-HH18, both complexed and non-complexed.
Large increases in the serum IgG2a response were observed in mice immunized and boosted
with each adjuvant platform combination tested. The differences between the responses to the
complexed adjuvant formulation, or the non-complexed formulation, and PTd alone were
statistically significant (p<0.001, and p<0.05, respectively). Immunization with the complexed
adjuvant platform vaccine also resulted in significantly (p<0.05) higher IgG2a titres as compared
to the non-complexed combination.
The IgG1 titres in this experiment followed a very similar pattern to the IgG2a response, with
adjuvant combinations inducing approximately 10 times higher titres than the antigen alone (Fig.
3.3B). There was no significant difference seen in the IgG1 titres between the complexed and
non-complexed vaccine groups, however, the mouse to mouse variability in antibody titre was
larger in the non-complexed vaccine groups.
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Figure 3.3 PTd-specific neonatal serum Ab responses to immunization with adjuvant platform combinations.
Neonatal BALB/c mice (n=8 mice per group) were immunized with either 1.0g PTd antigen alone (▲), PTd
(1.0g)+ CpG C(2.37g)+ IDR-HH18(35.55g)+ VIDO-EP#3(2.37g), with the IDRP & CpG components
complexed (■), PTd (1.0g)+ CpG C(2.37g)+ IDR-HH18(35.55g)+ VIDO-EP#3(2.37g), with the IDRP & CpG
components not complexed (▼), or PBS (●, n = 5 mice per group) at 7 days of age. An identical secondary
immunization was given at 4 weeks. Sera were collected at 4 weeks after the initial immunization prior to the boost,
and every 2 weeks thereafter until 8 weeks post-initial immunization. The median titres are shown. A) At week 6 to
8, statistically significant differences in IgG2a antibody titres occurred between either the complexed adjuvant
platform combination (p<0.001) or the non-complexed platform (p<0.05) relative to PTd treated mice. There was
also a statistically significant difference in IgG2a antibody titres (p<0.05) seen between the complexed and non-
complexed adjuvant platform combinations. B) At week 6 to 8, statistically significant differences in IgG1 titres
occurred between the complexed or non-complexed adjuvant platform relative to PTd treated mice (p<0.001).
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3.3.4. Variations of the Adjuvant Ratio in Neonatal Mice
In vitro evidence indicated that an adjuvant ratio of 1:2:1 (CpG ODN: IDRP: PP) was most
effective at increasing chemokine production in vitro [120]. In our previous experiments, a
differing ratio of 1:15:1 was being used, thus, a comparison of the two adjuvant ratios was
performed. Neonatal 7-day old mice were immunized with vaccine formulations either
containing 1.0 g PTd alone, or consisting of the 1:15:1 ratio containing 1.0 g PTd, 2.37 g
CpG, 35.55 g of IDR-HH18, and 2.37 g VIDO-EP#3 (complexed); or the 1:2:1 adjuvant ratio
containing 1.0 g PTd, 2.37 g CpG, 4.74 g of IDR-HH18 and 2.37 g VIDO-EP#3
(complexed). A control group received 1.0 g PTd combined with 2.5 g alum (aluminum
phosphate), the commercially used adjuvant that induces characteristically strong Th-2 type
immune responses.
A large increase in the IgG2a titres already occurred after the first immunization with either
ratio of the adjuvant platform formulation, as compared to antigen alone (Fig 3.4). This
difference was statistically significant for both adjuvant platform groups over the course of the
experiment. No significant difference was seen between the adjuvant platform combination
containing a dose of 35.55 g of IDR-HH18 (1:15:1 ratio) and the combination with the lower
4.74 g IDRP dose (1:2:1 ratio). Very low IgG2a titres were found in the PTd + alum immunized
group. Within this alum group, there were five non-responder mice and one late-responder out of
a total of 10 mice (Table 3.2). In the adjuvant combination group with 35.55 g of IDR-HH18,
all mice showed an IgG2a response and there were no late responders. In the adjuvant
combination group containing 4.74 g of IDRP, there was one mouse that was a late responder,
however all mice eventually showed an IgG2a response post-vaccination.
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Table 3.2. Individual IgG2a antibody responses and kinetics post-vaccination for Fig 3.4.
Vaccine Groupa Non-Rb Late-Rc Avg-Rd
Mouse
Total
PTd (1.0g) 1 6 3 10
PTd (1.0g) + CpG C (2.37g) + IDR-HH18 (35.55g) + VIDO-EP#3 (2.37g)
-complexed - - 10 10
PTd (1.0g) + CpG C (2.37g) + IDR-HH18 (4.74g) + VIDO-EP#3 (2.37g)
-complexed - 1 9 10
PTd (1.0g) + alum in PBSA (2.5g) 1 5 4 10
a Vaccine components of group, antibody titre results shown in Figure 3.4.
b Non-R = Number of "non-responding mice", a mouse that has non detectable antibody titre over the course
of the experiment
c Late-R = Number of "late-responding mice", a mouse that has no detectable antibody titre until 8 weeks post-
immunization or later
d Avg-R = Number of "average-responding mice", a mouse that has detectable antibody titre prior to 8 weeks
post-immunization
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Figure 3.4 PTd-specific neonatal serum IgG2a Ab responses to immunization with various adjuvant platform
combinations or alum.
Neonatal BALB/c mice were immunized with either 1.0g PTd antigen alone (▲), PTd (1.0g)+ CpG C(2.37g)+
IDR-HH18(35.55g)+ VIDO-EP#3(2.37g), with the IDRP & CpG components complexed (■), PTd (1.0g) +CpG
C(2.37g)+ IDR-HH18(4.74g)+ VIDO-EP#3(2.37g), with the IDRP & CpG components complexed (▼),
PTd(1.0g) + alum (2.5g) (x, n = 10 mice per group), or PBS (●, n = 9 mice per group), at 7 days of age. An
identical secondary immunization was given at 4 weeks. Sera were collected at 4 weeks after the initial
immunization prior to the boost, and every 2 weeks thereafter. The median titres are shown. Statistically significant
differences occurred between the adjuvant platform combination containing 35.55 g IDRP and the combination
containing 4.74 g relative to PTd-alone treated mice (p<0.005, and p<0.05, respectively). There was also a
statistically significant difference found between the adjuvant platform combination containing 35.55 g of IDRP
and the PTd and alum group (p<0.01). There were no differences between the two adjuvant platform combination
formulations.
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3.3.5. Duration of Immunity
The antibody levels of the group containing an adjuvant ratio of 1:2:1 were followed over a
longer period of time to examine when they would decrease (Fig 3.5). Very high IgG2a titres
were induced after immunization and boosting, and these titres remained elevated at the highest
level for approximately 52 weeks. Past this point, the antibody titres decreased slightly, however,
the IgG2a antibody response remained highly elevated for over 22 months.
Figure 3.5 PTd-specific neonatal serum IgG2a Ab responses to immunization with a 1:2:1 ratio of
CpG:IDRP:PP adjuvant combinations over an extended time period.
Neonatal BALB/c mice were immunized as in Fig 3.4, with an adjuvant platform combination, (n = 10 mice per
group) at 7 days of age. An identical secondary immunization was given at 4 weeks. Sera were collected at 4 weeks
after the initial immunization prior to the boost, and every 2 weeks thereafter, until week 10, after which sera were
collected approximately every 4 weeks. Median titres are also indicated for each group.
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3.3.6. Comparison of Single and Double Immunizations with a Commercial Vaccine
The ability of these adjuvants to induce a response comparable with, or ideally superior, to
that seen after immunization using a commercial vaccine and the response to one or two doses
were examined.
Vaccine formulations consisted of 1.0 g PTd, 2.37 g CpG ODN, 4.74 g IDR-1002, 2.37
g VIDO-EP#3, as well as the commercial vaccine Quadracel®. The IDR-1002 and CpG ODN
components were complexed. Single and double immunization groups for the adjuvant platform
combination and Quadracel®were included. IDR-HH18 was replaced by a third generation
synthetic IDRP, IDR-1002 (VQRWLIVWRIRK-NH2) because of its ability to induce superior
chemokine responses in vitro and in vivo [76]. Neonatal mice were immunized subcutaneously
with the formulations and the IgG2a serum responses were compared (Fig. 3.6).
A large increase in IgG2a titre was seen after both a single and a double immunization with
the adjuvant platform formulations, as compared to PTd antigen alone; however there was a
noticeable difference between the single dose and the boosted groups, with the boosted group
developing much higher titres. Immunization with the commercial Quadracel® vaccine, currently
used for infant vaccination, resulted in very low to negligible IgG2a titres after a single dose,
with an increase in titre occurring when boosted. However, even within the boosted Quadracel®
group, the resulting IgG2a titres were still lower than or similar to those that occurred in the
single dose adjuvant platform group. The antibody titres in the boosted adjuvant platform group
were significantly higher than those of the single dose commercial vaccine group. All mice in the
boosted adjuvant platform group showed an antibody response, while there were two non-
responding mice in the single dose group (Table 3.3). In comparison, six of the mice that
received a single dose of Quadracel® did not produce a detectable IgG2a response, with the
boosted group containing two non-responders. The IgG2a antibody response in the adjuvant
platform and Quadracel® groups remained elevated for over four months.
Thus it appears that through using the adjuvant platform formulation, a greater Th-1 immune
response can be induced, even after a single immunization, than that seen with a commercial
vaccine.
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Figure 3.6 PTd-specific neonatal serum Ab responses to single or double immunization with PTd formulated
with adjuvant platform combinations or the commercial vaccine Quadracel®.
Neonatal BALB/c mice were immunized with either PTd (1.0g) +CpG C(2.37g)+ IDR-HH18(4.74g)+ VIDO-
EP#3(2.37g), with the IDRP & CpG components complexed (▲, single dose), PTd (1.0g) +CpG C(2.37g)+
IDR-HH18(4.74g)+ VIDO-EP#3(2.37g), with the IDRP & CpG components complexed (■, two doses),
Quadracel® (n = 10 mice per group) with a dose including 1.0g chemically detoxified PTd (▼, single dose),
Quadracel® (x, two doses), or PBS (●, n = 9 mice per group) at 7 days of age. An identical secondary immunization
was given at 4 weeks to some groups. Sera were collected at 3 weeks after the initial immunization, and also at 8, 10
and 14.5 weeks post-initial immunization. The median titres are shown. Statistically significant differences occurred
between 2 doses of the adjuvant platform relative to a single dose of Quadracel® (p<0.05) treated mice.
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Table 3.3. Individual IgG2a antibody responses and kinetics post-vaccination for Fig 3.6.
Vaccine Groupa Non-Rb Late-Rc Avg-Rd
Mouse
Total
PTd (1.0g) + CpG C (2.37g) + IDR-1002 (4.74g) + VIDO-EP#3 (2.37g)
. -complexed & single dose 2 - 8 10
PTd (1.0g) + CpG C (2.37g) + IDR-1002 (4.74g) + VIDO-EP#3 (2.37g)
. - complexed - 1 8 9
Quadracel® (dose includes 1.0g chemically detoxified PTd)
- single dose 6 1 3 10
Quadracel® (dose includes 1.0g chemically detoxified PTd) 2 3 5 10
a Vaccine components of group, antibody titre results shown in Figure
3.6.
b Non-R = Number of "non-responding mice", a mouse that has non detectable antibody titre over the course of
the experiment
c Late-R = Number of "late-responding mice", a mouse that has no detectable antibody titre until 8 weeks post-
immunization or later
d Avg-R = Number of "average-responding mice", a mouse that has detectable antibody titre prior to 8 weeks
post-immunization
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3.4 Discussion
Whooping cough remains a major threat to infants and children in the developing world, with
serious complications resulting from the disease including encephalopathy, convulsions, brain
damage, and death (reviewed in [23]). Current pertussis vaccines cannot be administered until 6-
8 weeks of age, as prior to this time several factors, including the presence of maternal antibodies
and the innate Th-2 bias of the infant immune system, can modulate response to vaccination.
Since neonates are known to be the most severely affected by whooping cough, a protection gap
exists prior to the possibility of immunization, during which infants are at serious risk. To
circumvent this gap a novel neonatal vaccine formulation, able to successfully overcome infants’
Th-2 bias as well as the interference of maternal antibodies, is required.
Combinations of adjuvants may be used to induce superior immune responses than achieved
by single adjuvants alone. It has been found that the simultaneous stimulation of several TLRs
using multiple adjuvants in mice can improve the affinity maturation and neutralizing antibody
production in vaccinated animals [121]. This positive modulation effect is not seen with alum,
the currently used adjuvant in most human vaccines, including pertussis vaccine. Using mixed
TLR ligands in vaccine formulations, the immune response can be increased until it reaches a
threshold of activation necessary for antibody maturation [121]. Co-administration of TLR-9
agonists has also recently been tested in humans and found to enhance affinity maturation of
specific anti-vaccine antibodies [86]. Because of this, we have sought to formulate effective,
multi-component-adjuvanted vaccines with a combination of a known TLR ligand and other
adjuvants to create a more balanced immune response and protect neonates against pertussis.
Three classes of adjuvants were selected. These act via complementary mechanisms and are
thus speculated to simultaneously activate the immune system in distinct ways. Class C CpG
ODN is a well characterized TLR 9 agonist, combining the mechanistic abilities of the other
CpG classes by inducing both the secretion of IFN- from pDC and the proliferation of B and
NK cells [81]. Although the precise mechanism of action of the polyphosphazene PCEP is
unknown, its adjuvant effects are suspected to result at least partially from a depot effect. The
depot effect of polyphosphazenes has been tested and shown strong potential for use in the
sustained controlled delivery of human growth hormone [129]. Polyphosphazenes have been
shown to stimulated increased cytokine production, and it is also speculated that they may
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stabilize antigens, allowing more efficient presentation to immune cells [98, 130]. IDRPs have a
plethora of immunomodulatory effects; however, their ability to recruit cells to the site of
injection and activate DCs, resulting in increased APC function is speculated to be important for
increasing the cellular immune response necessary to clear B. pertussis infection.
Evidence from this report indicates that the combination of PTd antigen plus CpG C, IDR-
HH18 or IDR-1002, and VIDO-EP#3 has advantages over the use of each adjuvant individually
or as a doubly adjuvanted vaccine formulation. Vaccination using the developed complexed
adjuvant platform was found to result in the earlier onset of the IgG2a antibody response in both
adults and neonates. This was a distinct asset when compared to the responses to vaccination
with PTd antigen alone, antigen adjuvanted with alum, a single-dose of licensed Quadracel®
vaccine, and using the non-complexed adjuvant platform.
When the immune response to vaccination with PTd antigen was examined with each
adjuvant individually in adults, it was found that both CpG ODN and PP were able to
significantly increase IgG2a titres, indicating an enhanced Th-1 immune response, as compared
to PTd only. Class C was selected due to its unique ability to combine the effects of the other
classes. The selection of the PP VIDO-EP#3 was based on its ability to induce higher IgG2a
titres, and thus a stronger Th-1 immune response than VIDO-PP#4 in the absence of CpG ODN
after a primary injection. Also, overall, a higher proportion of immunized mice were able to
produce detectable IgG2a titres when this VIDO-EP#3 was used. Immunization with IDRPs
alone as an adjuvant failed to increase IgG2a titres. A possible explanation is that the IDRPs are
working through a different mechanism than the other adjuvants, for example it is well
understood that IDRPs do not interact with TLRs but do modulate signal transduction
downstream of TLRs and demonstrate synergy with IDRPs including CpG ODN [78, 131].
However, since the likely effect of this component is enhancement of the recruitment of immune
cells, the apparent inability of IDRPs to affect the IgG2a response by themselves may be
irrelevant. IDRPs are known to have chemotactic effects on immune effector cells, and our
synthetic IDRPs have been shown to induce increased production of chemokines in vitro and in
vivo [120]. Their cell recruitment effect may possibly be achieved through changing the
microenvironment at the vaccination site, resulting in increased APC recruitment and subsequent
increases in cytokine production that results in an increased cellular immune response.
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When we combined CpG ODN and IDRP together in a complexed precipitate form, a
significantly stronger and earlier IgG2a response occurred in both adult and neonatal mice over
that seen when the components were added separately. A higher dose of IDRP also resulted in a
higher proportion of mice responding with detectable IgG2a to vaccination. The indication is that
IDRPs have an effect on the ability of the mice to respond to the vaccine antigen by producing
antibodies, and thus IDRPs may in fact result in an increase of the Th-1 immune response. This
would indicate that the addition of a certain amount of the IDRP component allows the required
threshold of activation needed for antibody maturation to be reached. The absence of a detectable
antibody response in some mice within a vaccine group, while the other mice develop a very
good response, supports the supposition that there is a stimulation threshold necessary to achieve
activation of the humoral response.
After selection of each single adjuvant, these were combined together with PTd antigen to make
an adjuvant platform combination vaccine. In adult mice vaccinated with the selected adjuvant
platform, the IgG2a and IgG1 serum antibody titres were significantly increased as compared to
immunization with antigen alone. This indicates an enhancement of the overall, as well as
support of a Th-1 immune response. Immunization with the adjuvant platform vaccine in adult
mice was able to induce a higher and longer-lasting immune response than single adjuvants
alone. Complexation was found to cause a large increase in antibody production, with the
greatest enhancement of IgG2a titres resulting after a 75 g IDRP dose, with a lower 10 g dose
of IDRP appearing to have a lesser effect, although the difference was not statistically
significant. There are several other known functions of IDRPs, such as activation and maturation
of dendritic cells and chemokine induction, which were not assessed in using the readouts of
IgG1/IgG2a titres. These functions may be very important in inducing a strong overall immune
response to our vaccine formulations. PTd alone at the dosages used was found to be very poor at
inducing an IgG2a response, and somewhat better at inducing an IgG1 response, which was
commensurate with previous experiments performed. In particular, there were several IgG2a
non-responder mice seen in the PTd only group, with some mice in this group also failing to
produce an IgG1 response to the antigen. It is notable that mice in the 75 g/mouse IDRP
complexed group all had a measurable IgG2a and IgG1 response to vaccination, with no late
responders, indicating that complexing not only increased the overall immune response in these
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mice, it enabled us to ensure that mice that might not otherwise respond to vaccination would do
so.
Immunization in the neonates with the adjuvant platform combination was found to induce
significantly higher IgG2a responses than PTd antigen alone, confirming the ability of the
formulation to increase the Th-1 response, even within a model less likely to respond in a Th-1
type fashion. The results of the complexing of the IDRP and PP components mirrored those seen
in the adult mouse model, with significantly higher IgG2a titres occurring after the components
were complexed. This further indicates that complexing the components has an important effect
on the ability of the vaccine combinations to induce a Th-1 response, although we do not know if
this involves co-localization of components or genuine synergy between associated components.
The neonatal mice were found to respond with detectable IgG2a titres to both the antigen alone
as well as to the adjuvanted groups. A possible explanation for this is the higher dose of antigen
being used to vaccinate in the neonatal model. When neonatal mice were immunized using alum
as an adjuvant, the IgG2a response was almost non-existent, and was significantly lower than the
response induced by the adjuvant platform combinations. This was expected, as alum is an
adjuvant that typically induces a Th-2 type immune response [132].Within the alum group, there
was a 50% IgG2a non-response rate among the mice, indicating a poor Th-1 response being
induced when using this adjuvant. Since alum is currently used to adjuvant human acellular
pertussis vaccines, the ability of our adjuvant platform to induce superior IgG2a titres is
promising.
When neonatal mice vaccinated with the adjuvant platform were followed long term over
nearly two years, the IgG2a antibody titres were shown to remain elevated over the entire period.
This indicates that the Th-1 immune response being induced by the platform formulation is not
only superior in magnitude to that achieved after immunization with PTd only, but that it is also
a long-lasting response.
When the ability of the adjuvant platform formulation to induce an immune response after a
single immunization was examined, it was found that, although the IgG2a titres were superior
following a second immunization, the titres seen after a single dose were still greater than those
induced by a single dose of the commercial Quadracel® vaccine, and appeared in fact to be
similar to two doses of that vaccine. In addition, the number of mice responding to vaccination
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with a detectable IgG2a titre was superior in the groups given our adjuvant platform as compared
to those that received Quadracel® vaccine. All mice that were boosted with the adjuvant platform
showed an IgG2a response, however there were two mice in the Quadracel® vaccine group that
did not respond. At a single dose, only two mice did not produce a detectable IgG2a response in
the adjuvant platform group, as compared to six non-responders for the single Quadracel® dose.
Thus it appears that through using the current adjuvant platform, a greater Th-1 immune
response could be induced than that seen with a commercial vaccine, and a good IgG2a Ab
response might be induced even after a single immunization.
In conclusion, we have shown that through use of our adjuvant platform, a greater Th-1
immune response could be induced than that seen with a commercial vaccine, and a good IgG2a
Ab response appeared to be induced even after a single immunization, which is substantially
fewer than the three to five doses currently required for commercial acellular vaccines. Overall,
the adjuvant platform formulation has the potential to improve the balance of the neonatal
immune response to pertussis, allowing an earlier, stronger, and more effective response to be
mounted to deal with infection. Further characterization of the mechanisms involved in the
change of the immune response is needed to optimize these formulations.
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CHAPTER 4: CELL MEDIATED IMMUNE RESPONSES AND PROTECTION IN
ADULT AND NEONATAL MICE TO IMMUNIZATION WITH NOVEL BORDETELLA
PERTUSSIS VACCINE FORMULATIONS
4.1 Introduction
The disease whooping cough results from infection with the Gram-negative bacterium
Bordetella pertussis and Bordetella parapertussis. It is generally a childhood illness, and is seen
in both developed and developing countries [11, 122, 133]. The neonate and very young children
are the most susceptible to the disease, especially those who have never been immunized or have
not completed their full series of immunizations, and the majority of the morbidity and mortality
are seen within these groups [11, 133]. Although in several developed nations, a series of 5 doses
of acellular pertussis vaccine are given to children over the period from 2 months of age until 5
years, strong herd immunity is not effectively created due to the waning immune responses to the
vaccine over time [134]. In addition there are age-cohort effects where older children with
incomplete immunity are able to infect younger children or infants, which has led to a resurgence
of the disease in nations that were thought to not be significantly affected by this problem [17].
B. pertussis is able to function as both an extracellular and an intracellular bacterium, usually
attaching to the epithelial cell surface of the respiratory tract, but also able to invade human and
mouse lung macrophages [6]. Thus, both cell-mediated immune responses and humoral
responses are needed to effectively protect against and clear pertussis infection [22, 25, 27].
However, the exact mechanisms of protective immunity to the disease remain unknown, and it
has been shown that it is possible for vaccine protection to occur in the absence of detectable
circulating antibody [26, 135]. As well, IFNproduction, CD4+ Th1 cells and Th17 cells play an
important role in protection against this disease [24, 25]. The whole cell pertussis vaccine (Pw) is
known to induce superior levels of Th1 and Th17 cells as compared to the acellular pertussis
vaccines (Pa), however due to safety concerns, their use has been discontinued in many
developed nations [136, 137]. Thus it would be useful to develop a vaccine that is able to
combine the effective stimulation of Th1 cell-mediated immune responses seen in the Pw
vaccines, with the safety afforded by acellular vaccines.
54
Human infants have difficulty mounting certain immune responses, including those to T cell-
independent type 2 antigens [38]. The response is seen as functionally polarized in a Th2
direction, with less antibody secretion and less potent Th1 cell-mediated immune responses able
to be induced in both human and mouse neonates [36, 37, 138]. This leads to difficulties when
attempting to vaccinate neonates against diseases, such as pertussis, that require strong Th1
responses for clearance. However, studies indicate that the Th2 bias can be overcome through
strategies that include the efficient use of adjuvants such as multiple TLR ligands, and effective
antigen dosing and route of administration, such that immunization at or soon after birth can be
made effective [124, 138].
We have recently described a novel three component adjuvant platform with three components
for use in immunization against B. pertussis [139]. The three adjuvant components are C-class
CpG oligodeoxynucleotides (CpG ODN) as TLR-9 ligand and strong Th1-promoting adjuvants;
Polyphosphazenes (PP), a synthetic polymer with proven adjuvant activity and antigen
encapsulation abilities; and cationic innate defense regulator peptides (IDRP), representing host
defense molecules that have been shown to induce cell recruitment and modulate innate
immunity [72, 82, 99]. After characterizing the humoral responses in adult and neonatal mice to
vaccination with various combinations of these adjuvants, the present study was undertaken in
order to examine the cell-mediated immune responses to this adjuvant platform, as well as to
determine whether this vaccine formulation would function to protect neonatal mice against
infection with B. pertussis. Our results are promising, and indicate that this adjuvant platform is
highly effective in the mouse model in inducing superior immunity and protection as compared
to current vaccines.
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4.2 Materials and Methods
4.2.1. Animals
Seven-week old male and female BALB/c mice were obtained from Charles River Laboratories
(Wilmington, MA). Mice were kept at the VIDO Animal Care facility (University of
Saskatchewan, Saskatoon, SK), and bred to obtain neonates. Adult mice were used for
immunization experiments at 8 weeks of age. There were n = 8 mice per group for all cytokine
experiments, and n = 10 mice per group for the bacterial challenge experiment. Mice were
selected at random for cage assignments, with each cage housing mice from at least two different
groups. For sampling, mice were selected at random in equal numbers from each cage housing
that group. For the bacterial challenge experiment, five mice from each group were sampled on
both days 4 and 7. Animal technicians were not blind to the group assignment of mice, however
those performing the experiments were. All animal experiments followed the guidelines of the
University of Saskatchewan and the Canadian Council for Animal Care.
4.2.2. Animal Immunizations and Sample Collection
Adult mice were immunized at 8 weeks of age, and given a secondary immunization after four
weeks unless otherwise noted. Neonatal mice were immunized at 7 days, weaned from their
dams at four weeks, and received a secondary immunization at five weeks of age unless
otherwise noted. For cytokine experiments, both adult and neonatal mice were sacrificed and
spleens removed at five days after the secondary immunization. For bacterial challenge
experiments, animals were sacrificed and their lungs removed at three weeks, three weeks four
days, and four weeks after secondary immunization. For subcutaneous immunizations, both adult
and neonatal mice were immunized between the shoulder blades with 50 L of vaccine or sterile
phosphate- buffered saline (PBS; 1.54 mM KH2PO4, 155.17 mM NaCl, 2.71 mM Na2HPO4-
7H2O, Gibco, Invitrogen; Carlsblad, CA). For intramuscular immunizations, neonatal mice were
immunized in the quadriceps muscle with 10 L of vaccine or sterile PBS. To complex the IDRP
and CpG adjuvants within the vaccines, the components were mixed together and co-incubated
in a 1.5mL Eppendorf tube (VWR; West Chester, PA) for 30 minutes at 37°C.
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Blood was collected from the tail veins of mice. Samples were centrifuged in a microcentrifuge
at 5940 g for 5 min, and the sera removed and stored at -20° C until used for ELISA. Spleens
were aseptically collected into 15 ml centrifuge tubes (VWR; West Chester, PA) containing 10
mL of RPMI media (Gibco, Invitrogen; Carlsblad, CA). To isolate splenocytes, spleens were put
through a 40 M BD Falcon™ cell strainer (BD Biosciences; Bedford, MA) and washed at
21,885 x g for 10 min in RPMI media. Red blood cells were then lysed with 1 mL of NH4Cl lysis
buffer for 30 seconds, followed by another wash using 10 mL of RPMI at 21,855 x g for 10 min.
Two more identical washes were performed, after which the cells were resuspended in AIM-V
media (Gibco, Invitrogen; Carlsblad, CA) at various concentrations for counting and stimulation.
4.2.3. Vaccine Components
Genetically detoxified pertussis toxoid (PTd) was received from Novartis Vaccines (formerly
Chiron, Siena, Italy) [128]. Each batch of PTd was centrifuged at 1,350 x g for 10 min prior to
storage in aliquots at -20 °C. Frozen aliquots were thawed at room temperature (RT) and
centrifuged at 1350 x g for 10 min, after which the supernatants were used in vaccine
formulations or stored at 4 °C. CpG class C ODN 10101 was purchased from Coley
Pharmaceuticals (Ottawa, ON). The IDR-1002 was synthesized by the solid state phase fMOC
method, after which de-protected IDRPs were cleaved from the resin [76]. Purification utilized
reverse phase HPLC, followed by lyophilization. Before use in vaccine formulations, IDRPs
were resuspended in de-ionized water and diluted to the appropriate concentration in sterile PBS.
The polyphosphazene VIDO-EP#3 (PCEPP) was synthesized at the Idaho National Laboratory
(Idaho Falls, ID) under the supervision of Dr. John Klaehn, using a previously described method
[99]. Polyphosphazenes were received in the lyophilized form and stored at 4° C in the dark.
Before use in vaccine formulations, stored polyphosphazenes were dissolved by shaking for 36
hours at RT in Dulbecco’s PBS (1.54 mM KH2PO4, 155.17 mM NaCl, 2.71 mM Na2HPO4-
7H2O, Sigma-Aldrich, MO). The DTaP-IPV vaccine used was Quadracel® (Sanofi Pasteur,
Toronto ON), which was purchased from the University of Saskatchewan’s Western College of
Veterinary Medicine (Saskatoon, SK). A human dose of 0.5 mL contains 20 g of chemically
detoxified pertussis toxoid (PT), 20 g filamentous hemagglutinin (FHA), 5 g fimbrial
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agglutinins 2 and 3 (FIM), 3 g pertactin (PRN), 15 Lf diphtheria toxoid, 5 Lf tetanus toxoid, 40
D-antigen units poliovirus type 1 (Mahoney), 8 D-antigen units poliovirus type 2 (MEF1), 32 D-
antigen units poliovirus type 3 (Saukett), and 1.5 mg of aluminum phosphate aduvant. The
dosage of vaccine used for immunization was adjusted so that the concentrations of the PTd
component in the Quadracel® and the PTd component of our vaccine formulation were equal.
4.2.4. Detoxification of Pertussis Toxin
To obtain pertussis toxoid for use in ELISA and cytokine assays, aliquots of pertussis toxin
glycerol were purchased from List Biological Laboratories Inc. (Campbell, CA) and chemically
detoxified. For each g vial, 1.4 g of formaldehyde was added and the mixture incubated at
37°C for 2 hours, after which 25l of 1M L-lysine was added to quench the reaction. The
solution was then dialyzed using a Pierce Slide-A-Lyzer 2K MWCO dialysis cassette (Thermo
Fisher Scientific; Rockford, IL) in dialysis buffer (PBS, 0.5M Urea) over 2 days at 4°C, with 3
buffer changes. The concentration of the detoxified protein was then quantified using a Micro
BCA protein assay kit (Thermo Fisher Scientific; Rockford, IL).
4.2.5. In vitro Study of Splenocyte Cytokine Production
ELISA analysis of cytokine production:
Splenocytes were isolated and plated in Costar® 12 well cell culture cluster flat bottom
polystyrene plates (Corning Life Sciences; Lowell, MA) in AIM-V media (Gibco, Invitrogen;
Carlsblad, CA) at a concentration of 2.5 x 106 cells/well. Cells were then stimulated at 37°C for
72 h with either 5 g/ml List detoxified PTd or 2.5 g/ml Con A (Sigma-Aldrich, St. Louis, MO)
as a positive control. Plates were centrifuged at 21885 g for 10 min and the supernatant was
removed and stored at -80° C for later cytokine analysis. Cytokine ELISAs on the supernatants
were performed in 96-well polystyrene microtitre plates (Immulon 2 HB; Thermo, Milford,
MA), using DuoSet® ELISA kits (R&D Systems, Minneapolis, MN) for murine IL-5 and IFN-
and following kit instructions. After development with Streptavidin-HRP, plates were read
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using a SpectraMax® Plus384 Absorbance Microplate Reader (Molecular Devices; Sunnyvale,
CA) at a  of 450 nm with wavelength correction set at 540 nm.
ELISPOT analysis of cytokine production:
Ninety six well tissue culture plates (Immulon 2 HB; Thermo, Milford, MA) were coated
overnight at 4° C using primary rat anti-mouse IL-5 and IFN- specific monoclonal antibodies in
coating buffer (BD Pharmingen; San Diego, CA; 1.25 g/mL concentration). Splenocytes were
then isolated and plated in duplicate in AIM-V media (Gibco, Invitrogen; Carlsblad, CA), at a
concentration of 5 x 105 cells/well, and stimulated at 37°C for 24 h with either 5 g/ml
detoxified LIST PTd, 2.5 g/ml Con A, or AIM-V media as a negative control. Plates were then
incubated with biotinylated rat anti-mouse secondary antibodies (BD Pharmingen; San Diego,
CA; 1.25g/mL concentration) for two hours at RT, and developed with SigmaFAST™
BCIP®/NBT chromogen (Sigma-Aldrich, St. Louis, MO; dilution: 1 tablet/10 ml PBS). The
spots were counted using a Zeiss Stemi 2000 microscope. The median number of spots was also
calculated and indicated by a median line within each figure.
4.2.6. Analysis of PTd-specific antibodies by ELISA
Polystyrene microtitre plates (Immulon 2 HB; Thermo, Milford, MA) were coated with 0.25
g/mL detoxified List PTd antigen in coating buffer (15.0 mM Na2CO3 and 34.88 mM NaHCO3)
at 4 °C overnight, after which sera was added and plates incubated for two hours at RT. After
washing, goat anti-mouse IgG1 and IgG2a specific antibodies (Caltag Laboratories, Burlingame,
CA; dilution 1/10,000) were applied. Then streptavidin-conjugated alkaline phosphatase
(Jackson ImmunoResearch; West Grove, PA; dilution 1/5000, starting concentration 500 g/mL)
was added, followed by the substrate p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO;
dilution 1mg/mL). The iMark Microplate Reader (Bio-Rad; Philadelphia, PA) was used to
analyze the developed samples at a  of 405 nm with a reference wavelength of 490 nm.
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4.2.7. Bacterial Challenge with Bordetella pertussis
Mice (n = 10 per group) were challenged using 5 x 106 cfu/mouse of B. pertussis Tohama I strain
(obtained from Dr. Mark Peppler, University of Alberta, Edmonton, AB) in sterile PBS. The
challenge inoculum was determined by scraping the bacterial growth from several Charcol Agar
plates using 2mL of sterile PBS per plate. The plate growth was pooled and the resuspended
bacteria were strained into a 50mL centrifuge tube (VWR; Radnor, PA) and centrifuged using an
SS34 rotor in a Sorvall® Evolution RC Superspeed centrifuge (Thermo Fisher Scientific;
Rockford, IL) at 3,500 x g for 10 min at 16°C. The bacteria were then rinsed with PBS and
centrifuged once more at the same specifications. The OD600was then measured in order to
determine the challenge dose, with an OD600 of 1 equaling 2.5x 108 bacteria/mL.
The challenge was delivered intranasally to anesthetized mice, with 10L being inserted into
each nostril for a total volume of 20L.  To determine the challenge dose actually received
within the lungs, at 90 minutes post-challenge the lungs of two mice were removed into 2 mL
sterilized disposable conical microtubes with silicone O-rings (VWR; West Chester, PA)
containing approximately 0.5 mL of 2.3 mm Zircon/Silica beads (BioSpec Products; Bartlesville,
OK) and 1 mL of SS complete media. Samples were homogenized for 30 seconds using a Mini
Bead-Beater (BioSpec Products; Bartlesville, OK) set at speed level 1. Dilutions were plated
onto Charcoal agar plates containing 10% sheep blood, and incubated at 37° C for 7 days after
which bacterial colonies were counted. The same lung removal, homogenization, and plating
procedure was followed for the rest of the mice, with half the remaining mice being sacrificed at
four days post challenge, and the rest at day seven (n = 5 mice per group, per timepoint).
4.2.8. Statistics
Analysis of the data was performed using the Windows STATA 10 program (StataCorp LP,
College Station, TX). Graphs and scattergrams were plotted using the GraphPad Prism® 5
program for Windows (GraphPad Software Inc., La Jolla, CA).
Data was assessed for normality using the Shapiro-Wilk test. For repeated measures data, in
order to achieve a normal distribution, the sums of all of the repeated measures were taken, and
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these sums subsequently ranked. The resulting ranked data passed the normality test (p > 0.05).
For non-repeated measures data, the data was ranked, and the resulting ranks passed the
normality test. One-way ANOVA was used on the normally distributed data to determine the
presence of a significant difference between groups. Post-hoc tests used to separate the means
and identify which groups were significantly different included Bonferroni and Scheffe. A p-
value of p < 0.05 was considered statistically significant. For bacterial challenge experiments,
antibody titres were statistically analyzed separately both prior to and after challenge, as well as
together; for lung bacterial counts, each day was analyzed separately.
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4.3 Results
4.3.1. Cell mediated response to the adjuvant platform in adult mice
The mouse model is not an ideal correlate to the human, especially with respect to B. pertussis,
since infection in the mouse model does not reflect the clinical symptoms or pathology of the
human disease; nevertheless it is the accepted model for investigation of the pathophysiology of
pertussis [140].
After immunization with the vaccines and controls, boosting at four weeks, and removal of
spleens at five days post-boost, the isolated splenocytes were re-stimulated with 5 g/mL of PTd
for 24 h or 72 h (for ELISPOT and cytokine ELISA, respectively). The optimal kinetics of the
cytokine response in immunized mice and the optimal antigen stimulation dose and time points
for splenocyte response analysis were established in a series of pilot experiments (data not
shown). The ELISPOT analysis showed that there were IFN- producing cells present in all the
vaccine groups, ranging from a median of 94 spots up to 177 per group (Fig 4.1A). There was no
statistically significant difference in the number of IFNproducing cells seen between mice
immunized with our vaccine formulation as compared to those immunized with unformulated
PTd or DTaP-IPV (hereafter referred to as DTaP). Conversely, multiple spots indicating cells
producing IL-5 were seen in mice immunized with PTd alone or DTaP as compared to mice that
received our vaccine formulation, which showed virtually no cytokine production (with a median
number of spots of 2) (Fig 4.1B). The number of spots in these two IL-5 secreting groups ranged
from a median of 32 to 27, respectively. There was a statistically significant difference seen
between mice immunized with PTd alone or DTaP, as compared to those immunized with our
vaccine formulation, however there was no statistically significant difference between results for
the PTd alone and DTaP groups.
When the ratio of IFN : IL-5 producing cells was examined, it was shown that immunization
with our vaccine formulation resulted in a large increase in the ratio, from under 10 to a median
of 34, indicative of a shift in the type of immune response in favor of Th1 type immunity (Fig
4.1C).
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ELISAs to examine the concentration of cytokines produced were also performed (Fig 4.2A-B).
Strong production of more than 10,000 pg/mL of IFN- was seen after immunization with all
vaccines, with no significant differences observed between the groups (Fig 4.2A). This similarity
in measured cytokine production supports the ELISPOT data, which showed no significant
difference in the number of cytokine-producing cells detected. There was a significantly greater
amount of IL-5 produced in mice immunized with PTd alone or DTaP, as compared to those that
received our vaccine (Fig 4.2B). While there was detectable IL-5 production in the PTd and
DTaP groups with medians ranging from 162-56 pg/mL, respectively, there was no cytokine
detected in mice that received our formulated vaccine. There were no significant differences in
cytokine levels seen between mice that received PTd or DTaP, respectively. This once again
mirrored the results of the IL-5 ELISPOT.
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Figure 4.1 Adult IFN- and IL-5 ELISPOT responses to immunization with various vaccine formulations.
Adult BALB/c mice (n = 8 mice per group) were immunized with 0.1g PTd antigen alone (■), PTd (0.1g) + CpG
C(10g)+ IDR-1002(20g) + VIDO-EP#3(10g), with the IDRP & CpG components complexed (▼), or DTaP ,
with a dose including 0.1g chemically detoxified PTd (●) at 8 weeks of age. An identical secondary immunization
was given after 4 weeks. At 5 days post-boost, spleens were removed and splenocytes isolated and stimulated with
either media or 5.0g/mL of PTd for 24h. A) No statistically significant differences occurred in IFN- spot numbers
between any of the vaccinated mice. B) There were statistically significant differences in the IL-5 results between
mice treated with PTd alone or DTaP, as compared to PTd + the adjuvant platform (p<0.001). C) The ratio of
IFN:IL-5 cells was determined by dividing the number of IFN- spots for each animal by the corresponding number
of IL-5 spots.
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Figure 4.2 Adult IFN- & IL-5 cytokine ELISA responses to immunization with various vaccine formulations.
Adult BALB/c mice (n = 8 mice per group) were immunized with 0.1g PTd antigen alone (■), PTd (0.1g)+ CpG
C(10g)+ IDR-1002(20g)+ VIDO-EP#3(10g), with the IDRP & CpG components complexed (▼), or DTaP ,
with a dose including 0.1g chemically detoxified PTd (●) at 8 weeks of age. An identical secondary immunization
was given after 4 weeks. At 5 days post-boost, spleens were removed and splenocytes isolated and stimulated with
either media or 5.0g/mL of PTd for 72h. A) No statistically significant differences occurred in IFN- cytokine
levels between any of the vaccinated mice. B) Statistically significant differences in the IL-5 cytokine levels
occurred between mice treated with PTd alone or DTaP, as compared to those that received PTd + adjuvant
platform (p<0.001).
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4.3.2. Cell mediated response to adjuvant platform in neonatal mice
After completion of the cytokine studies in adult mice, we began experiments in a neonatal
mouse model. In order to use the best murine correlate to the human neonatal immune system,
seven-day old BALB/c mice were employed [36, 37]. These mice were immunized
subcutaneously with 50 L of vaccine, the spleens removed five days after a four-week booster
immunization, and the cytokine response of stimulated splenocytes determined through cytokine
ELISAs and ELISPOTs. Vaccine formulations included 1.0 g PTd, 2.37 g CpG ODN, 4.74 g
IDR-HH1002, and 2.37 g VIDO-EP#3, with the CpG and IDRP components pre-complexed.
The adjuvant dosages were decreased by a ratio relative to the body weight of the neonatal
mouse as compared to an adult, while the PTd dose was increased in order to compensate for the
reduced immune response of neonates to the antigen, as based on previous studies. After
immunization with the various vaccines and controls, boosting, and removal of the spleens,
isolated splenocytes were stimulated with 5 g/mL of PTd for 24 h or 72 h (for ELISPOT and
cytokine ELISA, respectively).
ELISPOTs showed a large number of F producing cells present in all of the vaccine
groups, ranging from a median of 145 spots to 202 in each group (Fig 4.3A). There were no
statistically significant differences in the number of IFNproducing cells seen between any of
the vaccine groups. These results and spot numbers are similar in range to those seen in adult
mice. For the Th2 type cytokine IL-5, spots were seen in mice immunized with PTd alone or
DTaP but very few spots were found in mice that received our formulated vaccine (Fig 4.3B).
The number of spots in the PTd and DTaP groups ranged from a median of 43 to 56,
respectively, higher than the number of spots seen in adult mice, although the trends within the
vaccine groups were the same. There was a statistically significant difference seen between mice
immunized with PTd alone or DTaP, as compared to those immunized with our vaccine
formulation, with no statistically significant difference noted between the PTd and DTaP
controls. When these results are expressed as a ratio, the number of IFN : IL-5 producing cells
indicated that immunization with either of our vaccine formulations resulted in a large increase
in the ratio, from less than 2 to a median of 45, which indicates a shift in the type of immune
response in the Th1 direction (Fig 4.3C).
67
ELISAs to examine the concentration of cytokines being produced were also performed on the
neonatal samples (Fig 4.4A-B). Strong production ranging from 4487-6674 pg/mL of IFN- was
seen after immunization with all vaccines (Fig 4.4A). There was no significant difference seen
between the vaccine groups, indicating that our vaccine did not affect the amount of IFNbeing
produced by the cells. This once again supported the ELISPOT data where there was also no
significant difference seen in the number of cytokine-producing cells. With respect to IL-5
production, there was a significantly greater amount of IL-5 produced in mice immunized with
PTd alone or DTaP, as compared to those that received our vaccine formulations (Fig 4.4B).
While there was detectable IL-5 production in the PTd and DTaP groups, medians of 185 and
108 pg/mL, respectively, there was effectively no cytokine detected in mice given our
formulated vaccine. There was no statistically significant difference seen between the PTd and
DTaP mice, once again matching the IL-5 and IFN- ELISPOTs.
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Figure 4.3. Neonatal IFN- and IL-5 ELISPOT responses to immunization with various vaccine formulations.
Neonatal BALB/c mice (n = 8 mice per group) were immunized with 1.0 g PTd antigen alone (■), PTd(1.0g)+
CpG C (2.37g)+ IDR-1002 (4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (▼),
or DTaP , with a dose including 1.0 g chemically detoxified PTd (●) at 7 days of age. An identical secondary
immunization was given after 4 weeks. At 5 days post-boost, spleens were removed and splenocytes isolated and
stimulated with either media or 5.0g/mL of PTd for 24h. A) No statistically significant differences occurred in
IFN- spot numbers between any of the vaccinated mice. B) There were statistically significant differences in the IL-
5 results between mice treated with PTd alone or DTaP, as compared to PTd + the adjuvant platform (p<0.001). C)
The ratio of IFN:IL-5 cells was determined by dividing the number of IFN- spots for each animal by the
corresponding number of IL-5 spots.
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Figure 4.4. Neonatal IFN- and IL-5 cytokine ELISA responses to immunization with various vaccine
formulations.
Neonatal BALB/c mice (n = 8 mice per group) were immunized with 1.0 g PTd antigen alone (■), PTd (1.0g)+
CpG C (2.37g)+ IDR-1002 (4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (▼),
or DTaP , with a dose including 1.0 g chemically detoxified PTd (●) at 7 days of age. An identical secondary
immunization was given after 4 weeks. At 5 days post-boost, spleens were removed and splenocytes isolated and
stimulated with either media or 5.0g/mL of PTd for 24h. A) No statistically significant differences occurred in
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IFN- cytokine levels between any vaccinated mice. B) Statistically significant differences in IL-5 cytokine levels
occurred between mice treated with PTd alone or DTaP, as compared to PTd + the adjuvant platform (p<0.001).
4.3.3. Protection of immunized neonatal mice against bacterial challenge with B. pertussis
Since vaccination with our adjuvant platform appeared to shift the cytokine response towards a
Th1 response, further experiments were undertaken in order to determine if our vaccine
formulations were able to protect in vivo against infection with B. pertussis. To examine this, an
intranasal bacterial challenge with 20 L of 5x106 cfu/mL B. pertussis Tohama I strain was
performed. Two mice were killed on the day of challenge in order to accurately assess the
inoculum dose achieved. Since the commercial DTaP vaccine contains 5 separate antigens, a
second pertussis antigen, pertactin (PRN), was included in some formulations, to test if addition
of a second antigen would increase the level of protection. Vaccine formulations consisted of
2.37 g CpG ODN, 4.74 g IDR-1002, 2.37 g VIDO-EP#3, combined with either 1.0 g PTd
or 5.0g PRN, or both PTd and PRN together as antigen (mixed together after complexing the
CpG and IDRP components), and compared to the commercial vaccine DTaP.The bacterial load
from the lungs of infected mice, as well as the PTd-specific IgG2a and IgG1 serum responses
were examined.
The PTd-specific antibody ELISA results showed that there was a significant increase
(more than 400 times higher) in PTd-specific IgG2a antibodies, indicative of a Th1 type immune
response, when mice were immunized with either of our vaccine formulations as compared to the
commercial DTaP vaccine (Fig 4.5A). It should be noted that vaccination with our vaccine
formulations was able to induce a strong IgG2a as early as three weeks post-immunization,
whereas mice that received DTaP did not show detectable IgG2a production until week five. A
very high IgG2a antibody titre of more than 1x 105 was reached with both of our vaccine
formulations, however the titre was significantly higher in mice vaccinated with the formulation
containing only the PTd antigen (reaching a maximum of 1.04 x 106), as compared to the
adjuvant formulation combined with PTd and PRN (which reached a titre of 1.91x 105). There
were two mice in the DTaP group that showed no detectable IgG2a response, and two that only
responded relatively late, after more than six weeks. There were no late or non-responding mice
in the groups that received any of our various adjuvant platform combinations. This result
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mirrored the lung bacterial loads, indicating that the inclusion of a second antigen significantly
increased the immune response to the formulated vaccines.
With respect to the PTd-specific IgG1 titres, indicative of a Th2 type immune response, there
were no significant differences seen between any of the vaccine groups (Fig 4.5B). All of our
vaccine formulations, as well as DTaP, were able to greatly increase the IgG1 response of the
mice, with the median titres ranging from 1 to 1.9x 106 by week six in all groups. Both the IgG2a
and IgG1 results mirrored our previously published data which indicated that our vaccine
formulations are superior inducers of IgG2a titres, while IgG1 titres remain approximately equal
to those seen using the commercial vaccine [139].
The bacterial loads at day zero were 5.03 x 106 colony forming units (cfu)/ lung (Fig 4.6). At
days four and seven, the bacterial load in the PBS control group had increased slightly, to a
maximum of 1.32 x107 cfu/ lung, whereas it had decreased greatly in all other vaccinated groups,
and was actually cleared completely in one mouse in the formulated dual antigen group. The
bacterial load in the vaccine group containing both PTd and PRN as antigens was significantly
lower than that seen in the group that received only PTd as an antigen, although both groups
were significantly lower than the PBS control. When compared to the untreated (PBS) control
goup, all vaccine groups showed a significant decrease in bacterial load. Nearly identically
decreased bacterial loads were seen in mice that were immunized with either DTaP or our
adjuvant platform using PRN as the antigen. However, it should be noted that a complete lack of
bacteria at day seven was only seen in mice of the vaccine group that received our adjuvant
platform combined with both PTd and PRN as antigens (there were three mice by the end of the
experiment with total bacterial clearance), indicating that this formulation was best able to
induce the appropriate immune responses necessary for total bacterial clearance.
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Figure 4.5. PTd-specific neonatal serum IgG2a and IgG1 Ab responses during challenge with B. pertussis.
Neonatal BALB/c mice (n = 10 mice per group) were immunized with PTd (1.0g)+ CpG C (2.37g)+ IDR-1002
(4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (●), PTd (1.0g) + PRN (5.0g) +
CpG C (2.37g)+ IDR-1002 (4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (▲),
DTaP, with a dose including 1.0 g chemically detoxified PTd (■), or PBSA (▼), at 7 days of age. An identical
secondary immunization was given at 3 weeks. Mice were challenged with 5 x 106 cfu/mL of B. pertussis at 3 weeks
post-boost.  Sera were collected at 3 weeks after the initial immunization prior to the boost, and at various times
thereafter. The median titres are shown. A) Statistically significant differences between the IgG2a titres occurred
between mice treated with PTd + adjuvant platform as compared to PTd +PRN + the adjuvant platform or DTaP
(p<0.001), as well as between the DTaP group as compared to the PTd + PRN + adjuvant platform group (p<0.001).
B) No statistically significant differences in IgG1 titre occurred between any of the vaccinated mouse groups.
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Figure 4.6. Neonatal lung bacterial counts after challenge with B. pertussis.
Neonatal BALB/c mice (n = 10 mice per group) were immunized with PTd (1.0g)+ CpG C (2.37g)+ IDR-1002
(4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (●), PRN (5.0g) + CpG C
(2.37g)+ IDR-1002 (4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG components complexed (▼), PTd
(1.0g) + PRN (5.0g) + CpG C (2.37g)+ IDR-1002 (4.74g)+ VIDO-EP#3 (2.37g), with the IDRP & CpG
components complexed (▲), DTaP, with a dose including 1.0 g chemically detoxified PTd (■), or PBSA (♦), at 7
days of age. An identical secondary immunization was given at 3 weeks. Mice were challenged as described in
Figure 5. Lungs were collected at 0, 4, and 7 days after bacterial challenge. The median t counts are shown.
Statistically significant differences occurred between mice immunized with PTd + adjuvant platform as compared to
PTd + PRN +adjuvant platform (p<0.005) on both day 4 and day 7, or as compared to DTaP (p<0.05) on day 4 only.
There were also statistically significant differences seen between mice immunized with PBSA as compared to all
other vaccine groups (p<0.01).
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4.4 Discussion
Whooping cough has re-emerged as a serious risk to infants in the developed world. Current
vaccines are unable to effectively protect against the disease without several booster doses,
cannot be utilized successfully prior to 6 weeks of age, and do not assure protection even if a full
vaccination schedule is followed. It is clearly necessary to develop new vaccines that can be
administered to and protect the most susceptible population, the neonate, and that will be fully
effective in their application. In order to achieve this, a vaccine must be capable of inducing
strong Th1 type humoral and cellular-mediated immunity in the neonatal system, as well being
able to overcome interference from maternal antibodies. We have addressed this challenge
through the combined use of the adjuvants CpG ODN, polyphosphazene, and IDR peptides. We
have previously shown that our adjuvant platform induces strong long-lasting Th1 type humoral
immunity, as well as the typically observed Th2 humoral immunity that is seen after
immunization with currently used commercial vaccines [139]. We have also addressed the issue
of maternal antibodies and found that the inclusion of a booster immunization and correct
formulation of adjuvants is able to overcome this issue [141].
The cell-mediated immune response to our adjuvant platform was examined through looking at
cytokine production post-vaccination. Our vaccine formulation was able to shift responses
towards a more balanced response through decreasing production of Th2 type cytokines. When
ELISPOTS for IL-5 and IFN- were performed to gauge the number of cytokine producing cells
in adult BALB/c mice, the results indicated that our vaccine formulations do not induce IL-5
secreting cells, while maintaining the levels of IFN- secreting cells, in contrast to mice
immunized with an alum adjuvanted, marketed acellular pertussis vaccine or antigen immunized
mice. The results were identical to those seen in neonatal mice, indicating that our vaccine
formulation is equally effective in both adults and neonates. It should be noted that the number
of IL-5 secreting spots detected by ELISPOT in mice immunized with PTd alone or the licensed
acellular pertussis vaccine was 26% and 52% higher in neonatal mice than the corresponding
number of spots seen in adult mice.
The cytokine ELISAs results showed the same trend, with the IL-5 concentrations detected
being approximately twice as high in the neonate as in adult mice, and the IFN- concentrations
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in the neonate being from 75% to 50% of those seen in adult mice. These results indicate a
tendency of the neonatal mice to produce an increased cellular Th2 response and lower, although
still strong, Th1 response in comparison to the adults. This may be due to the relative difficulty
of achieving a strong Th1 response in a neonatal system as compared to a mature adult one [38].
In previous experiments, we were able to demonstrate that PTd was a good model antigen with
respect to the humoral response, however when mice were bacterially challenged, we did not see
significantly reduced bacterial counts as compared to the licensed DTaP vaccine (data not
shown). However, through improvement of our formulation by inclusion of another pertussis
antigen, PRN, we have been able to surpass the alum adjuvanted marketed acellular vaccine
(which contains PT, PRN, FHA, and fimbriae) not only in the induction of a IgG2a humoral
response, indicative of a Th1 type response, but also in the ability to achieve bacterial clearance
in the lung. Although the alum adjuvanted DTaP vaccine is effective at inducing high IgG1
titres, indicative of a Th2 type response, it is not a strong inducer of IgG2a titres, whereas our
adjuvant platform, whether including a single or two antigens, is very capable of anti-PTd IgG2a
induction. Not only are the IgG2a titres far superior after vaccination with our formulations as
compared to DTaP (more than 400 times higher), they are detectable after only 3 weeks post-
immunization, as opposed to after 5 weeks with the commercial vaccine. After challenge of mice
with Bordetella pertussis, although DTaP was able to significantly decrease the bacterial load in
the lungs of mice, total clearance was only seen in mice that were immunized with our dual-
antigen adjuvant platform, indicating that we have been able to surpass the current vaccine in all
examined areas of the immune response, including humoral, cell-mediated, and effective
protective responses. Thus it appears that our vaccine formulations are inducing strong Th1 type
cell mediated immune responses in both adult and neonatal mice which are equivalent to those
seen using commercial vaccines, as well as a greater Th1 type humoral response than
commercial vaccines. These vaccine formulations may also function through decreasing the Th2
type cell mediated responses. Finally, our vaccine formulations are able to successfully induce
the immune response of neonatal mice in order to fully clear infection with B. pertussis.
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In conclusion, we have demonstrated that our novel adjuvant platform is not only able to
induce a shift in the adult and neonatal humoral response towards a Th1 type immune response,
but that there is also a corresponding decrease in the Th2 cytokine responses, and vaccination
results in protection against bacterial challenge in the neonate. This indicates that our vaccine
formulation promotes an overall balancing of the immune response in the adult and neonatal
mouse system by shifting responses in favor of a Th1 type response. Despite the traditional limits
of the mouse model we have achieved a strong shift in the immune response, with corresponding
protection against B. pertussis infection that is superior to currently available vaccines. The type
of immune responses seen with our vaccine formulation corresponded to the results needed in
order to create an effective human neonatal vaccine, and thus we believe that this adjuvant
platform is very promising.
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CHAPTER 5: ALTERATION OF ADJUVANT CHARACTERISTICS WITHIN A
NOVEL BORDETELLA PERTUSSIS VACCINE FORMULATION AND ITS EFFECT
ON THE IMMUNE RESPONSE IN MICE.
5.1 Introduction
Identifying adjuvants able to induce strong and lasting responses in susceptible populations such
as neonates or the elderly is key for the successful development of vaccines that will be effective
for these groups.  In the elderly, the involution of the thymus as well the low output of naïve T
and B cells makes successful stimulation and thus primary immunization difficult [142-144]. The
neonatal immune system is functionally immature, and characterized by lower shorter-lasting
vaccine-induced antibody responses and a Th2 type immune response that precludes the
development of the strong Th1 response required for dealing with intracellular pathogens [36].
This is due to a variety of factors, including the functioning of neonatal DC as well as the
immaturity of the follicular DC network and germinal centers in the neonate [39, 44]. However,
adult-like cellular immune responses can be generated in the neonate through the use of
appropriate adjuvants [145].
Currently, there is an interest in the use of multiple or combination adjuvants to attempt to
overcome some of the difficulties faced when attempting to vaccinate specific populations
including the immuno-compromised, neonates, and the elderly, with immune responses that
differ from those seen in healthy adults. The ability to link innate and adaptive immunity through
the use of appropriate adjuvants involving the stimulation of pattern recognition receptors such
as TLRs, has been previously demonstrated in our lab and others [100, 146]. Through
incorporating TLR ligands as adjuvants the immune response to several vaccines has been
improved, including Hepatitis B and RSV [86, 115, 121]. TLR ligands in vaccines appear to
significantly enhance the affinity maturation process and lead to the production of antibodies
with higher antigen-binding affinity [86, 121]. We have previously shown that the combination
of several adjuvants, including the TLR ligand CpG ODN, cationic innate defense regulator
peptides, and polyphosphazenes, are able to induce strong humoral Th1-type responses in adult
and neonatal mice when combined with a B. pertussis vaccine antigen [139]. This adjuvant
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combination is not only able to induce a strong humoral response in the neonate, but is also able
to overcome interference with maternal antibodies in both mice and pigs, which is another major
barrier to successful infant immunization [141]. We have recently demonstrated that this
adjuvant platform is also able to induce strong cell-mediated immune responses in both adult and
neonatal mice, and when a second antigen is added, the vaccine developed is protective against
bacterial challenge with B. pertussis (submitted for publication).
CpG ODN are synthetically developed unmethylated DNA sequences that mimic bacterial
DNA and act as TLR 9 ligands. There are three separate classes, each with its own functional
abilities [81]. A-Class CpG ODN strongly stimulate plasmacytoid DC resulting in
IFNsecretion, B-Class are able to stimulate the activation of B cells and increase the
production of antibodies, and C-Class combine the activities of both previous classes [81].
All CpG ODN are well-characterized as Th-1 promoting adjuvants, and CpG ODN have been
tested in many animal trials as well as in clinical trials in humans for vaccines against Hepatitis
B [87].
Poly I:C is a synthetic dsRNA which acts as a TLR 3 ligand. As such, it is able to induce IFN
production and the maturation of DC [47]. In humans and mice, only mDC express TLR 3 (as
opposed to the pDC), and TLR 3 is unique among TLRs since it is preferentially expressed in
mature DC. An attractive feature of dsRNA as a potential adjuvant is its ability to signal in both
a MyD88-dependent, and MyD88-independent manner. This was shown through its ability to
induce activation of NF-kB in MyD88 knockout mice, although no dSRNA induced production
of inflammatory cytokines was observed.
Polyphosphazenes are linear polymers composed of an inorganic phosphorus-nitrogen backbone
that have great flexibility in structure through their ability to incorporate various side groups
[95]. They are capable of being formed into microparticles for such varied uses as drug delivery,
tissue matrix development, and vaccine antigen or adjuvant protection and delivery [95]. In
addition, they have been shown to have potent immunostimulatory properties and can act as
vaccine adjuvants in their own right, with different PP inducing slightly different immune
responses [98, 99]. The ability of PP to act as adjuvants is not limited to their being covalently
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linked to the vaccine antigen, as water-soluble non-covalent complexes are able to form when
antigen and PP are merely mixed together [96]. The immune response seen with PP tends to be a
mixed Th1/Th2 type response, although PCPP has been demonstrated to induce more of a Th2
type immune response, with lower IFN- production than PCEP, which induces strong vaccine
induced antigen-specific responses that include both IFNand IL-4 production [99].
Cationic innate defense regulator peptides (IDRP) are naturally occurring (or derived from)
molecules found in almost all species. These peptides are amphipathic, small, positively charged,
and produced by a variety of host cells including phagocytes and mucosal epithelial cells [66,
126]. They are induced by the presence of pathogens and have multiple and varied functions,
including direct antimicrobial activity, cytokine and chemokine induction, and wound healing
[126]. The use of these peptides as vaccine adjuvants is relatively new, however they have
shown promise as treatments for infection, and are able to modulate the innate immune response
[75]. The synthetic peptide IDR-1002 has been shown to increase leukocyte recruitment through
the increase production of the chemokine MCP-1 [76].
A vaccine that is effective through multiple methods of administration (intranasal,
subcutaneous, etc.) is highly desirable, since the route of administration can be adapted to the
particular circumstances being faced in the field at the time of immunization. This would be of
particular use in the developing world, where access to some components of health care, such as
clean needles, can be limited. Within the context of an adjuvant platform, the ability to use
several routes of administration would allow various vaccines to be tailored to fit the route of
infection of the particular pathogen being immunized against.
The characterization of the immune response after vaccination at multiple simultaneous injection
sites allows the possibility of vaccine interference to be examined. The purpose of this study was
to further characterize the developed novel adjuvant platform, and we show that this platform is
able to function with different antigens, induces inflammatory cell recruitment, and is able to
increase the immune response post-vaccination in a site-specific and localized manner.
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5.2 Materials and Methods
5.2.1. Animals
Adult BALB/c mice were obtained at seven-weeks old from Charles River Laboratories
(Wilmington, MA), and housed in the VIDO Animal Care facility (University of Saskatchewan,
Saskatoon, SK). These mice were bred in-house to obtain neonates. Mice were selected at
random for cage assignments, with each cage housing mice from at least two different groups.
For sampling, mice were selected at random in equal numbers from each cage housing that
group. Animal technicians were not blind to the group assignment of mice, however those
performing the experiments were. Animal experiments were performed following the guidelines
of the University of Saskatchewan and the Canadian Council for Animal Care.
5.2.2. Immunization of mice
Adult mice were immunized at 8 weeks of age and given a secondary immunization after four
weeks unless otherwise noted. Neonatal mice were immunized at 7 days of age, weaned at four
weeks of age, and received a secondary immunization after four weeks unless otherwise noted.
For subcutaneous immunizations, adult mice were immunized between the shoulder blades with
50 L of vaccine or sterile phosphate- buffered saline (PBS; 1.54 mM KH2PO4, 155.17 mM
NaCl, 2.71 mM Na2HPO4-7H2O, Gibco, Invitrogen; Carlsblad, CA). For intramuscular
immunizations, adult mice were immunized in the semimembranosus muscle of the right or left
leg, with 20 l of vaccine or sterile PBS per injection site; neonatal mice were immunized in the
same muscle with 10 L of vaccine or sterile PBS.  For intranasal immunizations, neonatal mice
were immunized with 20L of vaccine or sterile PBS. Complexing of the IDRP and CpG
adjuvant components within vaccines was achieved through mixing together the components and
co-incubating them at 37°C for 30 minutes in a 1.5mL Eppendorf tube (VWR; West Chester,
PA). Blood was collected from the tail veins of mice. Blood was centrifuged for 5 minutes in a
microcentrifuge at 5940 x g in order to separate the sera, which was removed and stored at -20°
C for use in ELISAs.
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5.2.3. Vaccine components
Genetically detoxified pertussis toxoid (PTd) was kindly provided by Novartis Vaccines
(formerly Chiron, Siena, Italy) [128]. Each batch was centrifuged at 1,350 x g for 10 min and
stored in aliquots at -20 °C. Frozen aliquots were thawed at room temperature (RT) and
centrifuged at 1350 x g for 10 min, after which the supernatants were used in vaccine
formulations or stored at 4 °C. CpG class C ODN 10101 was purchased from Coley
Pharmaceuticals (Ottawa, ON). The IDR-1002 was synthesized by the solid state phase fMOC
method, after which de-protected IDRPs were cleaved from the resin [76]. Purification was
performed through reverse phase HPLC, followed by lyophilization. Before use in vaccine
formulations, IDRPs were resuspended in de-ionized water and diluted to the appropriate
concentration in sterile PBS. The polyphosphazene VIDO-EP#3 (PCEPP) was synthesized at the
Idaho National Laboratory (Idaho Falls, ID) under the supervision of Dr. John Klaehn [99].
Polyphosphazenes were received in the lyophilized form and stored at 4° C in the dark. Before
use in vaccine formulations, stored polyphosphazenes were dissolved by shaking for 36 hours at
RT in Dulbecco’s PBS (1.54 mM KH2PO4, 155.17 mM NaCl, 2.71 mM Na2HPO4-7H2O, Sigma-
Aldrich, MO).
Poly I:C was purchased from Sigma-Aldrich (St.Louis, MO). Hepatitis B surface antigen
(HBsAg) was purchased from Fitzgerald (North Acton, MA).
5.2.4. Preparation of samples for analysis
Following injection, sites were circled using permanent non-toxic marker, and lesion samples
were removed using scissors to cut out the affected area, or through taking of a punch biopsy.
For time-course experiments, the entire semimembranosus muscle was removed and sent for
analysis. Samples were placed in tissue cassettes and stored in 10 % buffered formalin solution
for transport to the University of Saskatchewan Prairie Diagnostic Services laboratory for
histological analysis by Dr. Brendan O’Conner. Pathologist was blind to content of treatments,
however group numbers were noted.
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5.2.5. Histological analysis of samples
Received tissues were cut through the lesion if visible, or in half through the centre if not, and
both new surfaces trimmed. Both surfaces were then placed inside a tissue cassette for further
histological processing. Tissue samples were stained using hematoxylin and eosin stain (H&E
stain), and stained samples were then analyzed for myopathy due to necrosis, inflammation
indicated by the presence of heterophils, vasculitis, lymphadenitis, and the presence of hair shafts
in the sample.
5.2.6. Detoxification of Pertussis Toxin
Pertussis toxoid used for ELISA assays was chemically detoxified from aliquots of pertussis
toxin that were purchased from List Biological Laboratories Inc. (Campbell, CA). For each
g vial of PT in glycerol, 1.4 g of formaldehyde was added and the mixture incubated at
37°C for 2 hours, followed by 25l of 1M L-lysine to quench the reaction. The detoxified
solution was dialyzed within a Pierce Slide-A-Lyzer 2K MWCO dialysis cassette (Thermo
Fisher Scientific; Rockford, IL) in dialysis buffer (PBS, 0.5M Urea) over 2 days at 4°C, with
buffer changes. Detoxification was confirmed by Chinese hamster ovary cell cytotoxicity assay
(CHO assay). Increasing concentrations of detoxified protein were incubated with CHO cells and
cell death analyzed. The detoxified protein concentration was determined using a Micro BCA
protein assay kit (Thermo Fisher Scientific; Rockford, IL).
5.2.7. ELISA analysis of antigen-specific Abs
Polystyrene microtitre plates (Immulon 2 HB; Thermo, Milford, MA) were coated for PTd-
specific ELISAs with 0.25 g/mL detoxified List PTd antigen, and for HBsAg-specific ELISAs
with 1.0 g/mL HBsAg, each in coating buffer (15.0 mM Na2CO3 and 34.88 mM NaHCO3) at 4
°C overnight, respectively. Sera was then added and the plates incubated at RT for two hours,
followed by washing and the addition of goat anti-mouse IgG1 and IgG2a specific antibodies
(Caltag Laboratories, Burlingame, CA; dilution 1/10,000). Streptavidin-conjugated alkaline
phosphatase (Jackson ImmunoResearch; West Grove, PA; dilution 1/5000, starting concentration
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500 g/mL) was added, and then the substrate p-nitrophenyl phosphate (Sigma-Aldrich, St.
Louis, MO; dilution 1mg/mL). Developed samples were read using the iMark Microplate Reader
(Bio-Rad; Philadelphia, PA) at a  of 405 nm with a reference wavelength of 490 nm.
5.2.8. Statistics
Data were statistically analyzed using the STATA 10 program for Windows (StataCorp LP,
College Station, TX). Normality of data was examined by Shapiro-Wilk test. To achieve a
normal distribution of data, the sums of all of the repeated measures were taken, and these sums
subsequently ranked. The resulting data passed the normality test (p > 0.05). One-way ANOVA
was used on the transformed data to determine the presence of a significant difference between
treatment groups. Post-hoc tests used to determine the specific differences between groups
include Bonferroni and Scheffe. A p-value of p<0.05 was considered statistically significant.
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5.3 Results
5.3.1 Testing the adjuvant platform with a different antigen
In order to test the versatility of our adjuvant platform and its ability to affect the immune
response to other antigens, HBsAg was co-formulated with the adjuvants and used for
immunization. 8-week old adult BALB/c mice were immunized intramuscularly with 20 L of
vaccine, boosted after four weeks, and the sera obtained at two week intervals in order to
determine the HBsAg-specific IgG2a and IgG1 serum responses through ELISAs. Vaccine
formulations included 0.3 g or a lower 0.03 g dose of HBsAg, 10 g CpG ODN, 20 g IDR-
HH1002, and 10 g VIDO-EP#3, with the CpG and IDRP components pre-complexed, with
Alum (25g) used as a control adjuvant.
ELISA analysis showed that immunization with our adjuvant platform and a 0.g dose
of HBsAg was able to induce strong IgG2a titres, 100-fold higher than alum, reaching a median
titre of 4.4x 105 (Fig 5.1A). Mice that received the higher antigen dose with our adjuvant
platform also had detectable IgG2a titres two weeks earlier than in the other vaccine groups. The
titres seen after immunization with a 0.3 g antigen dose and Alum as an adjuvant, were
comparable to those seen using a 0.03 g antigen dose and our adjuvant platform, with titres in
both these groups only detectable after 4 weeks, and only reaching a median of 2.3-8.3x 103.
Immunization with the 0.g dose of HBsAg and our adjuvant platform resulted in significantly
higher titres than those achieved in mice immunized with a ten-fold lower dose of antigen (0.3
g) and the adjuvant platform or with the same antigen dose but alum as the adjuvant. This
indicates a noticeable antigen dose-sparing effect seen when our adjuvant platform was used as
compared to Alum.
The IgG1 responses were comparable between alum and the adjuvant platform, with the adjuvant
platform and 0.3g HBsAg inducing a strong response reaching a median titre of 4x105, similar
to the antigen adjuvanted with alum, which reached a median titre of 1.3x 105 (Fig 5.1B). Titres
in both of these groups were significantly higher than those seen using the lower 0.03g antigen
dose combined with our adjuvant platform, which only reached a median titre of 2.5x 103. Thus
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the dose sparing effect noted above is only applicable to the IgG2a response. These results
indicated that our adjuvant platform was effective in enhancing the response to HBsAg, and was
able to enhance both the IgG2a and IgG1 (Th-1 and Th-2 type antibodies, respectively)
responses.
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Figure 5.1 Adult IgG2a and IgG1 humoral responses to immunization with various vaccine formulations
containing Hepatitis B Surface Antigen.
Adult BALB/c mice (n = 10 mice per group) were immunized intramuscularly with 0.03 g HBsAg + CpG C
(10g)+ IDR-1002 (20g)+ VIDO-EP#3 (10g), with the IDRP & CpG components complexed (●), HBsAg
(0.3g)+ CpG C (10g)+ IDR-1002 (20g)+ VIDO-EP#3 (10g), with the IDRP & CpG components complexed
(■), or HBsAg (0.3g) + Alum (25g) (▲), at 8 weeks of age. An identical secondary immunization was given after
4 weeks. Sera were collected every 2 weeks after the initial immunization for 10 weeks. The median titres are
shown. A) There were statistically significant differences  in the IgG2a titre between mice vaccinated with 0.3g of
HBsAg combined with the adjuvant platform, as compared to mice that received either the lower 0.03g antigen
dose, or 0.3g HBsAg with Alum as adjuvant (p<0.001). B) There were statistically significant differences in the
IgG1 titres between mice vaccinated with either 0.3g of HBsAg combined with the adjuvant platform or 0.3g
HBsAg and Alum, as compared to those that received 0.03g of HBsAg and the adjuvant platform (p<0.001).
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5.3.2 Histological time-course of antigen and adjuvant platform separately and in combination
In order to examine the histological changes and cell recruitment occurring after immunization
with the adjuvant platform, a time-course experiment was performed. To determine whether the
adjuvant platform (or the antigen alone) was acting through the induction of a systemic
inflammatory response, the vaccine components were administered separately in different legs of
the animal, with a combined vaccine control group included. Adult 8 week-old BALB/c mice
(n=20 mice per group) were immunized intramuscularly with 20l of the vaccine formulation per
leg (Table 5.1). Mice were boosted in the same manner after 3 weeks. The semi-membranous
muscle was removed at 3h, 7h, 24h, or 48h after immunization, and the biopsy was sent to
Prairie Diagnostic Services for histological examination by Dr.Brendan O’Connor. Results are
summarized in Table 5.2.
Table 5.1 Vaccine Groups for histological time-course of antigen and adjuvant platform
separately and in combination
Group Vaccine Formulation
1 PTd (0.1g)+ CpG C (10g) +HH-1002 (20g)+ EP3(10g)- complexed and injected in Right Leg
PBSA Injected in Left Leg
2 PTd (1.0g) Injected in Right Leg
CpG C (1.0g) + HH-1002 (20g) + EP3 (10g)- complexed and injected in Left Leg
3 PBSA Injected in Right Leg
PTd (0.1g) alone Injected in Left Leg
A very mild inflammatory response was present by 3h in the leg of Group 1 mice
following immunization with PTd and the novel adjuvant platform, with no vasculitis present.
This response had increased by 7 h to a moderately localized inflammatory response with an
increased presence of neutrophils (heterophils), indicating inflammation, and mild vasculitis.
This response remained increased through 48h post-immunization, however the vasculitis had
decreased almost completely by 24h, and was not detectable at 48h. In the leg of mice
immunized with antigen alone, there was mild or no inflammation seen at 3h. At 7h, there was a
very mild influx of neutrophils seen in approximately half of the mice immunized with antigen
89
alone, with little to no vasculitis present. There was some very mild inflammation in half of the
mice at 24h and 48h, however no vasculitis was detected. In the legs of the mice immunized with
adjuvants alone, there was mild inflammation seen by 3h with some influx of neutrophils, this
inflammation had not dissipated by 48h. The inflammation seen in the mice immunized with
both antigen and adjuvant at the same site was by far the most noticeable, with the legs receiving
either adjuvant or antigen alone showing much less inflammation. The response to each
component did not affect the responses occurring in the opposing leg, indicating that the vaccine
is likely not creating a systemic inflammatory response. This indicates that there is a localized
inflammatory response with vasculitis and a subsequent influx of neutrophils occurring when
mice are immunized with antigen combined with our adjuvant platform. This response does not
appear to be due to a systemic response to one of the components, since when the antigen and
adjuvant platform are separated, the inflammation is decreased. Although local lymph nodes
were present in approximately half of the samples examined, no lymphadenitis was noted within
them. The presence of hair shafts, presumably introduced by the injection needle, may have
caused some of the inflammatory response in samples where they were found.
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Table 5.2 Histological results and lesion scoring of muscle samples from time-course injections.
Group 1: PTd + Adjuvants (Right Leg) PBS (Left Leg)
Timepoint Necrosis Heterophils Vasculitis
Hair
Shafts Necrosis Heterophils Vasculitis
Hair
Shafts
3h 1 0 0 0 1 1 0 0
1 1 0 0 0 1 0 0
0 1 0 0 1 0 0 0
0 0 0 0 0 2 1 0
1 1 0 0 0 1 0 0
7h 2 3 1 0 0 0 0 0
0 2 1 0 0 2 0 3
0 2 1 0 0 2 1 1
0 3 1 0 1 1 0 1
1 2 1 0 0 0 0 0
24h 0 1 0 0 0 0 0 0
1 2 0 2 0 1 1 1
1 2 1 2 0 0 0 0
0 1 1 0 0 1 0 0
0 1 0 0 0 1 0 0
48h 1 3 0 0 0 1 0 0
0 2 0 0 0 0 0 0
0 2 0 0 0 0 0 0
1 1 0 0 0 2 0 1
1 2 0 0 0 0 0 0
Group 2: PTd (Right Leg) Adjuvant Combination (Left Leg)
Timepoint Necrosis Heterophils Vasculitis
Hair
Shafts Necrosis Heterophils Vasculitis
Hair
Shafts
3h 0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0
0 0 0 0 1 1 0 0
0 0 0 0 0 1 0 0
0 0 0 0 1 1 1 0
7h 0 2 0 2 2 2 1 0
0 0 0 0 1 1 1 0
0 0 0 0 0 0 0 0
0 0 0 0 1 1 1 1
0 1 0 1 0 1 0 1
24h 0 0 0 0 0 2 1 0
0 0 0 0 0 1 0 0
1 1 0 0 0 0 0 0
0 0 0 0 0 1 1 0
0 1 0 0 0 0 0 0
48h 0 0 0 0 0 2 0 0
0 0 0 0 0 2 0 0
0 0 0 0 0 2 0 0
0 0 0 0 0 2 0 0
0 1 0 1 0 1 0 0
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Group 3: PBS (Right Leg) PTd (Left Leg)
Timepoint Necrosis Heterophils Vasculitis
Hair
Shafts Necrosis Heterophils Vasculitis
Hair
Shafts
3h 0 1 0 0 0 1 0 0
0 1 0 0 0 0 1 0
0 1 0 0 0 1 0 0
0 0 0 0 0 0 0 0
1 1 0 0 1 2 1 0
7h 0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0
0 0 0 0 0 1 0 1
0 0 0 0 0 1 0 1
24h 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
1 1 0 0 1 1 0 1
0 0 0 0 0 1 0 0
0 0 0 0 1 2 0 1
48h 0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 2 0 2
0 0 0 0 1 1 0 0
Scoring
Legend 1 = Mild focal or multifocal change
2 = Moderate multifocal change or  mild locally-extensive change
3 = Moderate locally-extensive change
4 = Severe locally-extensive change
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5.3.3 Effects on antibody production of antigen and adjuvant platform separately and in
combination
Ideally, a vaccine will induce a localized immune response at the site of injection, so that if
other vaccines are administered at the same time, for example in a different limb, they will not be
affected by a heightened systemic response to the first vaccine. If other vaccine antigens are
present, interference can occur due to competition for M’s uptake of the antigen, resulting in the
ineffective T and B cell priming, and thus lower immune responses. If vaccinating in two arms,
there can be interference with circulating antibodies [147]. In order to ensure that the humoral
responses being induced by our vaccine platform are the result of a localized immune response
that is only induced by the presence of both components together (and thus would not have an
effect on a separate vaccine administered at a different site), we split our vaccine antigen and the
adjuvant platform and examined the responses to each component when injected together and at
separate sites.
8-week old adult BALB/c mice were immunized intramuscularly with 20 L of vaccine per
injection site, boosted after three weeks, and the sera obtained at two week intervals in order to
determine the PTd-specific IgG2a and IgG1 serum responses through ELISAs. Vaccine
formulations included 0.1g PTd, 10 g CpG ODN, 20 g IDR-HH1002, and 10 g VIDO-
EP#3, with the CpG and IDRP components pre-complexed.
The ELISA analysis showed that there was a strong induction of the IgG2a antibody response,
with a median titre reaching 7.5x 105, after immunization with PTd and the adjuvant platform
together at one site (Fig 5.2A). This response was significantly higher than that seen after
immunization with PTd alone, or with PTd at one site and the adjuvant platform in the opposing
limb (median titres up to 1.7 x103, and 1.0 x 103, respectively). The IgG2a response seen to PTd
alone was nearly identical to that seen when the adjuvant and antigen components were injected
in separate limbs.
The IgG1 results followed a similar trend as the IgG2a. The titres seen after immunization with
PTd alone or PTd in one leg and adjuvants in the other, were very comparable, with median titres
up to 3.2x 105 and 2.0x 105, respectively (Fig 5.2B). There was a significantly greater IgG1
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response when mice are immunized with the combined antigen and adjuvant combination at the
same site, reaching a median titre of 1.1x 106.
These results indicate that the antibody response induced to the vaccine is the result of a
localized immune response that requires the presence of both components at the injection site to
be induced.
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Figure 5.2 Adult IgG2a and IgG1 humoral immune responses to vaccination with antigen and adjuvant at
separate and distinct sites.
Adult BALB/c mice (n = 10 mice per group) were immunized intramuscularly with PTd (0.1g) + CpG C (10g)+
IDR-HH1002 (20g)+ VIDO-EP#3 (10g), with the IDRP & CpG components complexed – in the Right Leg (●),
PTd (0.1g) alone in the Right Leg and CpG C (10g) + IDR-HH1002 (20g)+ VIDO-EP#3 (10g), with the IDRP
& CpG components complexed – in the Left Leg (■), or PTd (0.1g) alone in the Left Leg (▲) at 8 weeks of age.
An identical secondary immunization was given after 3 weeks. Sera were collected every 2 weeks after the initial
immunization for 10 weeks. Muscle biopsies of the injection site were taken at 10 weeks and histologically
examined. Median titres are shown. A) There was a statistically significant difference in IgG2a titres found between
mice immunized with adjuvant platform and antigen together in the same leg, as compared to those given either PTd
alone, or separated PTd and adjuvant components (p<0.001). B) There was a statistically significant difference in the
IgG1 titres between mice immunized with the adjuvant platform and antigen together in the same leg, as compared
to those given either PTd alone, or the separated antigen and adjuvant components in different legs (p<0.001).
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5.3.4 Polyphosphazene safety profile in BALB/c mice
In order to examine the safety of the polyphosphazene component, high doses of
polyphosphazene alone (50g, 150g, or 300g) were given to adult BALB/c mice. After a dose
of 300g given subcutaneously, the bodies of the mice became visibly swollen and the mice died
within 5 days. At a dose of 150g, mice survived however they showed clinical signs such as a
rough coat and lethargy. These mice were boosted after 7 days and punch biopsies taken after 14
days and sent for histological analysis to Dr.Brendan O’Conner at Prairie Diagnostic Services.
The histological analysis indicated that, at the standard vaccine doses used for our neonatal or
adult mouse experiments, there were no lesions present at the injection site, and no significant
histological changes seen. For mice that received very high doses of PP, there were severe
lesions (epidermal necrosis) at the injection site, with deep perivascular dermatitis and mild
dermal fibrosis (fibroblast proliferation in the deep dermins and subcutis). There was a mixed
inflammatory cell infiltration, including neutrophils (heterophils), macrophages, lymphocytes
and plasma cells. Mast cells were also commonly present in the dermis. These lesions were also
present in mice vaccinated with a higher adjuvant platform dose including 0.1g PTd, 10 g
CpG ODN, 75 g IDR-HH18, and 50 g VIDO-EP#3 after 6 days (Fig 5.3).
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Figure 5.3 Visible lesions of mice post-vaccination with high doses of adjuvant platform.
Adult BALB/c mice (n = 20 mice per group) were immunized subcutaneously with PTd (0.1g)+ CpG C (10g) +
IDR-HH18 (75g) + VIDO-EP#3 (50g), at 8 weeks of age. Samples (punch biopsies) were taken from the lesion at
the injection site at 3, 6, 9, 12, 15, and 18 days post-immunization.
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5.3.5 Replacing CpG ODN with Poly I:C in the adjuvant platform
The synthetic analog of double-stranded RNA, Poly I:C, is a TLR3 agonist, and may be a
possible substitute for CpG ODN within our adjuvant platform.  In order to examine the effects
of replacing the CpG component with Poly I:C, 8-week old adult BALB/c mice were immunized
subcutaneously with 50 L of vaccine, boosted after four weeks, and the sera obtained at two
week intervals in order to determine the PTd-specific IgG2a and IgG1 serum responses through
ELISAs. Vaccine formulations included 0.1 g PTd, 10 g CpG ODN or Poly I:C, respectively,
20 g IDR-HH1002, and 10 g VIDO-EP#3, with the CpG (or Poly I:C) and IDRP components
pre-complexed.
ELISA analysis showed that immunization with our adjuvant platform containing Poly I:C or
CpG ODN induced significantly higher IgG2a titres, indicative of a Th1 immune response, as
compared to the vaccine containing antigen alone (Fig 5.4A). The titre after immunization with
the CpG ODN vaccine reached a median of 1.0 x 105,while the comparable Poly I:C vaccine
reached a highest median titre of  5.0x103. The IgG2a response after immunization with the CpG
ODN platform was detectable after only two weeks, notably earlier than the antibody responses
seen in mice given the adjuvant platform containing Poly I:C, which did not show a response
until six weeks after the first immunization (and two weeks after the booster dose).  The IgG1
response to vaccination with the adjuvant platforms containing Poly I:C or CpG ODN, indicative
of a Th2 type response, was not significantly different, with both vaccine groups as well as the
PTd alone group able to induce high IgG1 titres, reaching a median of 2.7 x 105 to 1.9 x 106 (Fig
5.4B).
Subsequently we wished to examine the possible effects of the route of immunization and the
Poly I:C component dose on the humoral immune response.  Thus another experiment was
performed in which 7-day old neonatal BALB/c mice were immunized either intramuscularly
(with 10L) or intranasally (with 20L) with our adjuvant platform, containing 1.0g PTd,
2.37g VIDO-EP#3, 4.74g IDR-HH1002, and either a 2.37g dose of CpG ODN, or various
doses (ranging from 0.1g to 10g) of Poly I:C. Mice were boosted after four weeks, and sera
obtained at 4, 6, and 10 weeks to determine the PTd-specific IgG2a and IgG1 serum responses
through ELISAs.
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After intramuscular immunization, all mice that received our adjuvant platform showed an
IgG2a response, with no significant differences seen between the group containing CpG ODN
and those groups containing Poly I:C (Fig 5.5A). There was no significant difference in response
found between the various dosages of Poly I:C, and all of our adjuvant platform vaccine groups
showed significantly higher titres than the PTd alone group.  By week 10, a strong IgG2a
response, with median titres ranging from 5.0x 105 to 5.5x 106, was seen in all of the adjuvant
platform groups that were immunized intramuscularly. When immunized intranasally, there was
a significantly higher IgG2a response in mice that received the adjuvant platform containing
CpG ODN, as compared to either the same (2.37g) or a higher (10g) dose of Poly I:C or to
antigen alone (Fig 5.5B). The titre in the mice that received the CpG ODN containing vaccine
reached 3.1x 105, as compared to 3.8x 102 in the mice receiving vaccines with Poly I:C.
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Figure 5.4 Adult IgG2a and IgG1 humoral responses to subcutaneous immunization with adjuvant platforms
containing CpG ODN or Poly I:C.
Adult BALB/c mice (n = 10 mice per group) were immunized subcutaneously with 0.1g PTd antigen alone (●),
PTd(0.1g)+CpG C(10g)+IDR-1002(20g)+VIDO-EP#3(10g), with the IDRP & CpG components complexed
(■), or PTd(0.1g)+Poly I:C(10g)+IDR-1002(20g)+VIDO-EP#3(10g), with the IDRP & Poly I:C components
complexed (▲), at 8 weeks of age. An identical secondary immunization was given after 4 weeks. Sera was
obtained before boost and at 2, 4, 6, 8, and 10 weeks post immunization, and used for ELISAs. The median titres are
shown. A) There were statistically significant differences in the IgG2a titre between mice immunized with PTd +
the adjuvant platform containing CpG ODN as compared to those that received PTd + adjuvant platform with Poly
I:C (p <0.05). Both adjuvant platform groups were statistically different from the mice that received PTd alone
(p<0.001 for the CpG ODN containing group and p<0.05 for the Poly I:C containing group respectively). B) There
were no statistically significant differences seen in the IgG1 titres between mice that were vaccinated with either
adjuvant platform or PTd alone.
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Figure 5.5 Neonatal IgG2a and IgG1 humoral responses to immunization through various routes with
adjuvant platforms containing CpG ODN or Poly I:C.
Neonatal BALB/c mice (n = 9 mice per group) were immunized with intramuscularly or intranasally with 1.0g PTd
antigen alone, PTd (1.0g)+ CpG C(2.37g)+ IDR-HH1002(4.74g)+ VIDO-EP#3(2.37g), with the IDRP & CpG
components complexed, or PTd (1.0g)+ Poly I:C (either 0.1g, 1g, 2.37g or 10g )+ IDR-HH1002(4.74g)+
VIDO-EP#3(2.37g), with the IDRP & Poly I:C components complexed at 7 days of age. An identical secondary
immunization was given after 4 weeks. Sera were collected at 4, 6, and 10 weeks after the initial immunization. The
median titres are indicated. 5A. No statistically significant differences in IgG2a titre were found between any
adjuvant platform groups. All groups immunized with the adjuvant platform showed statistically significant
differences from the mice treated with PTd alone (p<0.05). 5B. A statistically significant difference was seen
between mice that received the CpG ODN vaccine as compared to the Poly I:C version (p<0.005), or PTd alone
(p<0.001).There were also statistically significant differences in the IgG2a titres between mice treated with the
2.37g or 10g dose of Poly I:C,  as compared to PTd alone (p<0.01, and p<0.05, respectively).
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5.4 Discussion
The re-emergence of vaccine-preventable diseases such as whooping cough in the developed
world is worrisome. It emphasizes the need for the development of effectively adjuvanted
vaccines that are able to induce appropriate immune responses in susceptible populations, such
as neonates and the elderly. The adjuvants best suited for such a role will have to be both safe
and effective. We recently developed a novel multi-component adjuvant platform and tested it
with pertussis toxoid in adult and neonatal mice [139]. Here, we have shown here the versatility
and safety of this adjuvant platform.
To examine the versatility of the adjuvant platform, HBsAg was combined with our platform and
tested in adult mice. The adjuvant platform was able to induce significantly stronger IgG2a titres
and equally strong IgG1 titres as when the commercial vaccine adjuvant Alum was given with
the same antigen dose (Fig 5.1A/B). Even when the adjuvant dose was decreased by ten-fold, the
adjuvant platform was able to induce titres equal to those seen with Alum. These results were
supported by previous research, which indicated that the CpG ODN component was effective in
allowing lower doses of HBsAg to be used in vaccination in mice [148]. Thus, the adjuvant
platform was effective with other antigens as a humoral stimulator in mice.
Practical concerns must also be addressed when designing an adjuvant platform. During infancy,
there are several vaccines given in developed countries, often simultaneously. This makes the
type of immune response being induced by a vaccine even more important, since if the immune
response is non-specific and systemic, it may interfere with, or increase the side effects of, a
vaccine that is given at the same time at a different injection site. The histology of the injection
site in adult mice was examined after intramuscular injection with the PTd vaccine formulation
that had either been separated into its antigen and adjuvant platform components, or was
combined together (Fig 5.2A/B). The combined vaccine platform showed mild locally induced
inflammation at the injection site with an influx of heterophils by 7 hours post-injection, which
remained through 48 hours, indicating a vaccine-induced inflammatory response had been
created. However when the adjuvant platform and antigen components were administered
separately, the injection site inflammation was greatly reduced, with only a very mild reaction
seen at the site, indicating that when not given in combination with an antigen, the adjuvant
platform does not act through inducing systemic inflammation. This indicates that there may be a
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lack of interference when giving the platform at one site and a different vaccine at another. The
humoral immune response of the separated vaccine antigen and adjuvant platform components
was also examined (Fig 5.3A/B). Both the IgG2a and IgG1 responses were significantly higher
in the combined adjuvant and antigen groups than when the components were separated. For
IgG2a, only in combination was the antigen and adjuvant platform able to induce a strong
antibody response, and while there was a strong IgG1 response seen even with the components
separately, this can be attributed to the fact that the PTd antigen alone is capable of inducing
strong IgG1 antibody responses. These results supported the histological data, and further
confirm that the immune response being seen after immunization with our vaccine is a specific
response, which requires the presence of both the antigen and adjuvant platform to be induced.
The safety profile of some the PP component of the adjuvant platform was examined
histologically post-vaccination, and it was found that at the recommended dose there was no ill-
effect, although when administered in extremely high doses, there were toxic effects of the
polyphosphazene observed.
Combination adjuvants have proven highly effective, and the current trend is towards the use of
multiple TLR ligands as adjuvants in order to try and engage several inflammatory mechanisms
simultaneously and create synergy between the adjuvants. In order to increase the versatility of
the adjuvant platform, we attempted to replace some of the individual components. It has been
found that the TLR 3 ligand, the synthetic dsRNA Poly I:C, when complexed with IDR-1002,
was able to induce comparable MCP-1 production from human PBMCs in vitro (data not
shown). Thus we attempted to replace the CpG ODN component of our adjuvant platform with
Poly I:C for the subcutaneous vaccination of adult mice (Fig 5.4A/B). The humoral response
indicated that the CpG ODN component was more effective in increasing the Th-1 type IgG2a
titres as compared to Poly I:C. However, there was no difference seen in the IgG1 titres
achieved.
It has been previously shown that optimal protection using TLR ligands such as CpG ODN is
achieved when the adjuvant is delivered through the same route as the infectious agent [87].
Thus, we examined other routes of immunization in order to examine the effects this had on the
immune responses induced. (Fig 5.5A/B). When given to neonatal mice intramuscularly, Poly
I:C within our adjuvant platform was able to induce the same high titres as when the CpG ODN
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component was used, indicating that this may be a route of immunization for which the
replacement of the expensive CpG ODN component with Poly I:C would be feasible. However,
when given intranasally, the IgG2a humoral results mirror those seen when the vaccines were
given subcutaneously, and the adjuvant platform containing Poly I:C induces significantly lower
titres than a platform containing CpG ODN. These results emphasize the importance of route of
administration in the immune responses induced, and show that it may be possible in certain
situations, to alter the components of our adjuvant platform to adjust to the route of infection and
the particular pathogen being dealt with.
We have developed a multi-component adjuvant platform that is able to induce antigen-specific
localized site responses with several antigens. This platform is safe, inducing only mild
inflammation at therapeutic doses, and is able to be used through several routes of
administration, including subcutaneously, intramuscularly, and intranasally. The platform is also
versatile, with the ability to replace components and still achieve strong humoral responses
through some routes of administration, making it a strong candidate for further research in the
search for good neonatal adjuvants.
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CHAPTER 6: GENERAL DISCUSSION
There are several issues that make it difficult to achieve successful specific immune
responses to vaccines in neonates. There is an inherent Th2 bias in the infant immune system,
making the induction of strong and lasting Th1 type humoral and cell-mediated immune
responses difficult to achieve. Another important issue is the presence of maternal antibodies
which can interfere with vaccination and the achievement of a sufficient primary immune
response. Thus, the traditional adjuvants and routes of immunization used in adults, such as alum
or intramuscular immunization, may not be appropriate for use in the human infant. Therefore,
the development of an appropriate vaccine platform is of vital importance in order to be able to
protect infants from debilitating infectious diseases.
A successful neonatal vaccine should not induce tolerance to the antigen or elicit allergic
responses. In particular, a candidate neonatal vaccine must be extremely safe in order to avoid
adding to current circulating theories in the general population, many who may regard vaccines
as dangerous or as having severe side effects. These impressions can make a vaccine unattractive
and less likely to be accepted for use by parents. Towards this end, dose-sparing should be used
in order to minimize the amounts of antigen required, and thorough testing in neonatal animal
models such as the mouse and pig should be performed before moving into any human trials. A
gold standard vaccine for human neonates would be one that is able to create the pathogen-
appropriate “balanced” or “mixed” Th1/Th2, or, alternatively, Th1/Th2 biased responses and that
can generate long-lasting protective immunity. However, there is a functional immaturity of
some neonatal cells, which results in a Th2 cytokine milieu being present after stimulation,
making it difficult for antibody secreting cells to survive until the infant has reached a certain
age.
A balanced immune response is one that includes elements of both humoral and cell
mediated immunity in a manner that effectively protects by reducing infection and/or
pathogenesis. In the case of some diseases, such as those caused by infection with Leishmania,
there is a clear delineation of the required type of immune response, with a Th1 response
resulting in successful protection against or clearance of disease, and a Th2 response creating
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disease susceptibility and leading to non-healing lesions [149]. Other diseases, such as pertussis,
appear to be best combated with an immune response incorporating a more even distribution of
the Th1 and Th2 responses. As previously discussed, a cell-mediated immune response mediated
by IFN- helps to most effectively clear B. pertussis infection, however passive immunization
experiments have shown that a humoral response featuring Ab alone is also capable of conferring
some level of protection [23]. It appears that an ideal immune response for pertussis would thus
incorporate a mixture of features of both the Th1 and Th2 response, including strong humoral
and cell-mediated immunity. Although Th1 immune responses are required to confer protection
against numerous infectious diseases, a one-sided and prolonged Th1 type of response is not
always ideal, and in many cases can be detrimental to the host. The cell-mediated immune
response usually activates CTL in an antigen-specific fashion, with the CTL in turn destroying
cells displaying the antigen (e.g. virus-infected cells). Cell-mediated immune responses stimulate
cells to secrete a variety of cytokines that influence the function of other cells involved in the
adaptive and innate immune responses. It can also results in the activation of macrophages and
NK cells, enabling them to destroy intracellular pathogens. The cell-mediated immune response
can cause significant pathologies when excessively activated, such as in the case of Helicobacter
pylori infection, where a prolonged Th1 response is associated with peptic ulcer development in
the antrum of the stomach [150]. A strong Th1 response has also been implicated in the
pathogenesis of several other autoimmune diseases, including Crohn’s disease and multiple
sclerosis [151, 152]. Thus, when attempting to design a strategy for immune deviation, one must
consider that merely shifting a predominantly Th2 response to a Th1 or vice-versa may result in
the development of new pathologies instead of, or in addition to, the desired therapeutic effects.
Although the infant immune response is predisposed to the Th2 type, it is possible to
achieve strong Th1 responses, sometimes even approaching the levels seen in adults, through the
use of appropriate adjuvants with vaccine antigens. The most successful adjuvant additions to a
neonatal vaccine will most likely involve a combination of adjuvants that work through several
different immune pathways, ideally achieving a synergistic effect. This concept of using several
different adjuvants to attempt to promote a balanced response in the neonate led to the
development of the adjuvant platform examined for use with the antigen PTd. Through this study
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and those of our collaborators, we demonstrated that each individual adjuvant component used
was able to induce an immune response in combination with the PTd antigen that is greater than
that seen with the antigen alone. The responses appear to work through several mechanisms,
including increased antibody production and shift in the antibody subtype produced towards a
Th1 type, upregulation of IL-8 and the MCP-1 chemokine, which result in the attraction to the
site of infection of monocytes, memory T cells and DC, and the possibility of antigen
encapsulation and a depot effect allowing sustained induction of the immune response [66, 153].
One hypothesis is that the adjuvant platform is enabling the B cells in neonatal mice to reach a
“stimulation threshold” necessary for optimal antibody induction, and thus they successfully
produce strong antibody titres earlier than when using an alum adjuvant. The secondary IgG2a
response induced by our adjuvant platform in mice immunized as neonates was also extremely
long lived. Since mice exposed as neonates to antigen often produce IgG1-dominated secondary
antibody responses, this induction of Th1 memory by our vaccine is promising [154].
Vaccination with our adjuvant platform thus promoted a shift in the immune response in both
adult and neonatal BALB/c mice in the Th1 direction [139]. The adjuvant platform is also able to
successfully address the issue of MAb interference [141].
Our experiments also showed strong Th2 type Ab production following vaccination with
the adjuvant platform. The resulting IgG1 titres were equivalent to, and sometimes greater than,
the IgG2a. The strength of the IgG1 response may, at least in part, be explained by the mouse
model and antigen used. The BALB/c mouse is a Th2-biased model, with the MHC haplotype
H2d [155, 156]. This genetic background has been shown to effect the type of immune response
induced by some pathogens or antigens, with these mice often exhibiting predominantly Th2
type responses to exogenous antigen stimulation [156, 157]. However, under certain
experimental conditions, it has also been demonstrated that BALB/c mice do not always exhibit
Th2 responses and, depending on factors such as the dose of antigen used for priming, the innate
biases of a mouse strain can be overcome [157]. Another possible factor in the strength of the
IgG1 antibody response seen is the PTd antigen. Our data indicates that PTd antigen itself
induces a greater IgG1 response than IgG2a. We consistently saw little to no detectable IgG2a
response to PTd alone in adult mice, and very low IgG2a titres in neonates, who received a 10-
fold higher antigen dose. This hypothesis is further supported by our data examining the use of a
different antigen, HBsAg, in combination with the adjuvant platform. After immunizing mice
107
with HBsAg plus alum as an adjuvant, IgG2a titres of up to approximately 1x104 were
successfully induced. By comparison, when mice were immunized with PTd plus alum in
another experiment, the maximum IgG2a titre induced was approximately 5x102. The adjuvant
alum is a well-characterized promoter of Th2 and IgG1 antibody responses, thus it is unlikely to
be responsible for the increased IgG2a titres seen [158]. It appears that the HBsAg itself is a
better inducer of IgG2a antibody production than PTd. This mixture of a Th2 biased mouse
strain, and an antigen that tends to produce an IgG1 as opposed to an IgG2a antibody response,
may explain the results seen after vaccination with the adjuvant platform. The fact that the
platform is still able to induce a very strong IgG2a response in a Th2 biased mouse model using
an antigen that preferentially induces IgG1 responses in this model suggests that the adjuvant
platform is indeed successfully shifting the immune response in these mice towards the Th1
direction.
Given that our adjuvant platform induced a sustained cell-mediated immune response and
decreased Th2 cytokines, this indicates that it is able to promote a more balanced response in the
neonate, possibly through the inhibition of, or decrease in, the Th2 type cytokine milieu present
after immunization. Our results indicated low amounts of IL-5 produced in mice immunized with
antigen alone or the Quadracel® vaccine, with ablation of this production in mice that received
the adjuvant platform. This disappearance of detectable IL-5 and IL-5-producing cells may
appear to be at odds with the significant increase in IgG1 titres seen using the adjuvant platform.
A Th2 response is initially characterized by an increase in cytokines such as IL-4, IL-5, and IL-
13. These cytokines create an appropriate milieu for the interaction between Th2 type helper T
cells and cognate B naïve cells, which induces the B cells to differentiate, isotype switch, and
produce Th2 type antibodies such as IgE and IgG1 in the ensuing humoral response. However,
while IL-5 has been shown to be a correlate of the Th2 response, it is not the only factor that can
drive the secretion of IgG1. It has been shown in vitro that murine CD4+ Th1 clones are able to
induce IgG1 production, and that this antibody production is IL-5 independent , indicating the
possibility of more than one pathway for the induction of IgG1 synthesis [159]. It has also been
noted there is a lack of direct evidence showing that IL-5 contributes to the generation of in vivo
antibody responses [160]. Moreover, B cells have been shown to respond and secrete IgG1 to a
mixture of IL-4 and IL-6 independent of IL-5. Both IL-5 and IL-6 were found in vitro to
independently stimulate increases in steady-state levels of immunoglobulin and J-chain mRNA
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and proteins, as well as to induce differentiation of a murine B-cell lymphoma cell-line into
strong Ab-secreting cells [161]. These two cytokines appear to at least partially function through
distinct molecular pathways. In our experiments, the production of IL-6 was detected at a
consistent level (approximately 400pg/ml) from re-stimulated splenocytes of adult mice
immunized with our adjuvant formulation, as well as in mice that received antigen alone or
Quadracel® (data not shown). This IL-6 may play a role in the induction of the IgG1 responses
seen after vaccination with antigen alone. Studies have also found that CD4+ Th1 and Th2 cells
can differ in their ability to induce isotype specific Ab synthesis, with some clones being
superior to others [162]. This indicates that the ability of a T cell to secrete a characteristic
cytokine such as IFN- (seen at high levels in all of our vaccinated groups), does not necessarily
predict the functional capacity of that cell to induce antibody synthesis [162]. It has also been
shown that the ability of Th2 cells to induce T-dependent B cell responses in vivo is not unique
and that, following immunization, both Th1 and Th2 cells migrate into B cell follicles to support
B cell clonal expansion and Ab production [163]. This leads to a hypothesis that the adjuvant
platform is stimulating Th1 CD4+ T cells, that are then inducing the production of both IgG1 and
IgG2a responses. Another possibility is that the adjuvants are working synergistically to increase
both the IgG1 and IgG2a responses, as has been reported previously for bovine-respiratory
syncytial virus-specific IgG titres using vaccine combinations of PP and CpG ODN [116].
Finally, studies have shown that using different adjuvants and immunization regimes can
drastically affect the humoral response without necessarily influencing cytokine production
patterns by T-cells [164].
In both the humoral and cell-mediated responses in adult and neonatal mice, the ratio of
the characteristic Th1:Th2 type response is increased after vaccination with our adjuvant
platform. This ability to induce strong and balanced humoral as well as cell-mediated responses
in both adult as well as neonatal mice, culminated in the protection of immunized mice against
challenge with live B. pertussis. The adjuvant platform, when combined with only two antigens,
was able to surpass the protective efficacy of Quadracel®, the currently used vaccine in Canada
for infant immunization, which includes five pertussis antigens combined with an alum adjuvant.
When the antigen included in the vaccine platform was changed, a dose sparing effect and a
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strong Th1 immune response was still seen in adult mice, as compared to alum, indicating that
this platform has versatility and possible applications beyond that of just pertussis. Variation in
the routes of administration also indicated further ways in which the adjuvant platform may be
tailored to deal with other pathogens, with the platform showing promise as both a traditional
intra muscular and a mucosal adjuvant. This mucosal ability is particularly important, as it can be
a difficult area in which to achieve strong immune responses, and there are many pathogens
which enter through mucosal surfaces. The safety of the platform was demonstrated through its
lack of histological effects when it is administered without antigen, indicating that it causes a
site-specific localized immune response only when antigen is present, and not an increased
systemic response that could interfere with subsequent or simultaneous other vaccinations in the
neonate.
The issue of costs was examined through the replacement of the CpG ODN component,
technology to which there is limited access, with another TLR ligand Poly I:C. This tweaking of
the adjuvant platform showed promise as an intramuscular adjuvant, however there were
limitations in its abilities to function when used subcutaneous or mucosally. However, it may
still be possible to replace and exchange various components of the adjuvant platform and
achieve successful immune responses depending on the pathogen being addressed, its route of
infection, and the immune response required to successfully combat infection.
In summary, we have developed a novel vaccine formulation against B. pertussis, which
is able to induce strong humoral and cell-mediated immune responses, especially Th1 responses,
in both adult and neonatal mice, with the immune responses induced being long-lasting and
protective against infection. We have also demonstrated that our novel adjuvant platform itself is
adaptable for use with other vaccine antigens and through other routes of administration, and it
may be possible to adjust the platform components while maintaining efficacy.
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CHAPTER 7: CONCLUSION
7.1 Overall Conclusions
We have developed a novel vaccine against B. pertussis through the co-formulation of
multiple adjuvants, including CpG ODN, PP, and IDRP, along with the B. pertussis antigen,
PTd. This vaccine formulation is able to induce strong, long-lived Th1 and Th2 type humoral
immune responses in BALB/c adult and neonatal mice, with an especially notable increase in the
Th1 type IgG2a antibody response as compared to immunization with commercial pertussis
vaccines or the adjuvant alum. The cell mediated immune response in neonates and adults after
vaccination with the novel vaccine shows a decreased IL-5 response while a strong IFN-
response is maintained, confirming the mixed Th1/Th2 response seen humorally. When an
additional pertussis antigen, PRN, is included in the vaccine formulations, protection against B.
pertussis bacterial challenge can be achieved, with complete clearance of bacteria in many
animals, which is superior to the results seen with commercial vaccines in the same model. The
adjuvant platform is demonstrably versatile, and can be used with the HBsAg to induce a strong
Th1/Th2 response in adult mice, similar to that seen using PTd, with the IgG2a type antibodies
being significantly increased as compared to immunization using the standard vaccine adjuvant
alum. Finally, the novel vaccine platform has been demonstrated to recruit immune cells such as
neutrophils in a localized manner, with an inflammatory response and increased vasodilation
seen at the site of injection, and not in a systemic manner, with the presence of both the vaccine
antigen and adjuvant together required for the influx of immune cells to occur.
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7.2 Future Research
Further characterization of the cell-mediated immune response is necessary in order to
determine the mechanism of protection involved using this adjuvant platform. Examination of
the effects of the adjuvant platform on the DC subsets as well as the CD4+ and CD8+ T cells
induced and their cytokine production may be useful in order to better understand the exact role
these cells are playing in the protection of the mice against infection with B. pertussis. Further
studies in other animal models, such as pigs, are necessary to ensure that the platform is effective
within a better correlate of the human immune system, and a more extensive safety profile of the
vaccine must be compiled. Finally, clinical trials must be performed first in animals, and
eventually humans, for the overall efficacy and safety of the platform to be determined.
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